Engineering an improved adenovirus packaging cell line by Roberts, Pamela.
Engineering an Improved Adenovirus Packaging Cell Line
by
Pamela Roberts, B.Sc. (Hon)
Department ofBiological Sciences
A Thesis
Submitted to the Department ofBiological Sciences
in partial fulfillment of the requirements
for the degree ofMaster of Science
August, 2002
Brock University
St. Catharines, Ontario, Canada
©Pamela Roberts, 2002.
2ABSTRACT
Recombinant human adenovirus (Ad) vectors are being extensively explored for their use
in gene therapy and recombinant vaccines. Ad vectors are attractive for many reasons, including
the fact that (1) they are relatively safe, based on their use as live oral vaccines, (2) they can
accept large transgene inserts, (3) they can infect dividing and postmitotic cells, and (4) they can
be produced to high titers. However, there are also a number of major problems associated with
Ad vectors, including transient foreign gene expression due to host cellular immune responses,
problems with humoral immunity, and the creation of replication competent adenoviruses
(RCA).
Most Ad vectors contain deletions in the E1 region that allow for insertion of a transgene.
However, the E1 gene products are required for replication and thus must be supplied in trans by
a helper ceillille that will allow for the growth and packaging of the defective virus. For this
purpose the 293 cell line (Graham et al., 1977) is used most often; however, homologous
recombination between the vector and the cell line often results in the generation of RCA. The
presence of RCA in batches of adenoviral vectors for clinical use is a safety risk because tlley
. may result in the mobilization and spread of the replication-defective vector viruses, and in
significant tissue damage and pathogenicity. The present research focused on the alteration of
the 293 cell line such that RCA formation can be eliminated.
The strategy to modify the 293 cells involved the removal of the first 380 bp of the
adenovirus genome through the process of homologous recombination. The first step towards
this goal involved identifying and cloning the left-end cellular-viral jUl1ction from 293 cells to
assemble sequences required for homologous recombination. Polymerase chain reaction (PCR)
was performed to clone the junction, and the clone was verified through sequencing. The
plasn1id PAM2 was then constructed, which served as the targeting cassette used to modify the
3293 cells. The cassette consisted of (1) the cellular-viral junction as the left-end region of
homology, (2) the neo gene to use for positive selection upon tranfection into 293 cells, (3) the
adenoviral genome from bp 380 to bp 3438 as the right-end region of homology, and (4) the
HSV-tk gene to use for negative selection.
The plasmid PAM2 was linearized to produce a double strand break outside the region of
homology, and transfected into 293 cells using the calcium-phosphate technique. Cells were first
selected for their resistance to the drug G418, and subsequently for their resistance to the drug
Gancyclovir (GANC). From 17 transfections, 100 pools of G418f and GANCf cells were picked
using cloning lings and expanded for screening. Genomic DNA was isolated from the pools and
screened for the presence of the 380 bps using PCR. Ten of the most promising pools were
diluted to single cells and expanded in order to isolate homogeneous cell lines. From these, an
additional 100 G41Sf and GANef foci were screened. These preliminary screening results
appear promising for the detection of the desired cell line. Future work would include further
cloning and purification of the promising cell lines that have potentially undergone homologous
recombination, in order to isolate a homogeneous cell line of interest.
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1. INTRODUCTION AND LITERATURE REVIEW
1.1 HISTORY AND EPIDEMIOLOGY
Adenoviruses were independently discovered by two -groups of researchers (Rowe et al.,
1953, Hilleman and WeIner, 1954). While attempting to establish cell lines from the adenoids
removed from a number of children, Rowe and his colleagues discovered a cytopathic agent that
was causing the human adenoids to undergo spontaneous degeneration. These agents were
originally proposed to be designated as the "adenoid degeneration agent" or "A.D. agent" (Rowe
et al., 1953). Almost simultaneously, Hilleman and Werner were investigating an epidemic of
acute respiratory illness among military recruits. They isolated a previously unidentified
microbial agent from the throat washings of a patient with primary atypical pneumonia, and
found that the agent multiplied in human cell tissue cultures. The viruses isolated by the two
groups were soon shown to be the same virus.
Adenovirus infections can cause a number of clinical manifestations including respiratory
infections, conjunctivitis, hemoI14 hagic cystitis, and gastroenteritis (Table 1). Infants, children,
military recruits and immunocompromised individuals are the most susceptible to adenaviral
infections (Rubin and Rorke, 1988). Of all the adenovirus serotypes, Ad7 is the most severe
cause of respiratory infections, and Ad8 is responsible for the most severe outbreaks of
keratoconjunctivitis (reviewed in Wadell, 1994). Adenoviral respiratory infections, which are
extremely common in military recruits, lead to a condition refelTed to as ARD (Acute
Respiratory Disease). ARD is most commonly caused by Ad4, Ad? and occasionally Ad3, and
often occurs under the conditions of fatigue and crowding expelienced by military recruits
(reviewed in Horwitz, 1990a). After 25 years of successful control through immunization,
respiratory infections due to Ad? and Ad3 have reemerged to threaten the health of young adults
17
in the military (Ryan et al., 2002). Less commonly, adenoviral infections can be associated
with central nervous system infections including aseptic meningitis, meningoencephalitis and
encephalitis (Rubin and Rorke, 1988).
Table 1. Diseases caused by adenoviral infections (reproduced from Horwitz, 1990a)
Disease
Acute febrile pharyngitis
PharyngoconJunctival fever
Acute respiratory disease
Pneumonia
Pneumonia
Epidemic keraconJunctivitis
Pertussis-like syndrome
Acute hemorrhagic cystitis
Gastroenteritis
Hepatitis
Persistence of virus in urinary
tract
1.2 CLASSIFICATION
Individuals Most at Risk
Infants, young children
School-age children
Military recruits
Infants, young children
Military recruits
Any age group
Infants, young children
Infants, young children
Infants, young children
Infants and children with liver
transplants
AIDS, other immunosupression, and
bone marrow transplant recipients
Principal Serotypes
1,2,3,5,6,7
3, 7, 14
3,4,7,14,21
1,2,3,7
4, 7
8,11,19,37
5
11,21
40,41
1,2,5
34, 35
Adenoviruses belong to the family Adenoviridae, which is divided into two genera,
Mastadenovirus and Aviadenovirus. The Mastadenovirus genus includes more than 80
serologically distinct types of mammalian viruses including simian, bovine, equine, porcine,
canine and 47 types of human adenoviruses (reviewed in Doerfler, 1994). In 1993, two
additional human serotypes were recognized (Schnurr and Dondero, 1993), and recently
candidate Ad serotypes 50 and 51 were isolated from AIDS patients (De Jong et al., 1999). The
genus Aviadenovirus contains viruses isolated from avian species including fowl, turkey, goose,
pheasant and duck. There is no shared family-specific antigen among the Adenoviridae;
however, the genus Mastadenovirus does share a genus-specific antigen (reviewed in Wadell,
1994). Recently, a third genus has been proposed which would contain bovine adenoviruses
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(BAVs) 4-8, Ovine adenovirus (OAV) isolate 287 and egg drop syndrome (EDS) virus. The
proposed name of the genus is Atadenovirus, referring to the high genomic AT content of the
proposed members (Benko and Harrach, 1998; Dan et al., 1998).
The 47 human adenoviruses were originally classified into four groups on the basis of
hemagglutination patterns with rat and rhesus monkey red blood cells (reviewed in Horwitz,
1990b). Once it was discovered that human Ad12 could induce tumors in hamsters (Trentin et
al., 1962), it was then proposed that a new classification system should be used to divide the
human adenoviruses into genera based on their oncogenesis in newborn hamsters (reviewed in
Wadell, 1994). Currently the human adenoviruses are divided into 6 genera, A-F, based on their
hemagglutination patterns, oncogenicity in rodents, DNA base composition and homology,
restriction endonuclease patterns of the genome, viral polypeptide patterns and length of fibers
(Table 2).
Table 2. Properties ofhuman adenovirus serotypes of subgenera A-F
(reproduced from Wadell, 1994).
::"Subgenus Serotype G+C Hemagglutination Length Oncogenicity Tropism
(%) Pattern of in Newborn Symptoms
Fibers Hamsters
,(nm)
A 12,18,31 48 IV 28-31 High Cryptic enteric
infection
B 3,7,11,14, 51 9-11 Weak Respiratory
16,21,34, Disease, Persistent
35 infections of the
kidneys
C 1,2,5,6 58 III 23-31 Nil Respiratory
disease persists in
lymphoid tissues
D 8,9,10,13, 58 II 12-13 Nil Keratoconjunctiv itis
15,17,19,
20,22 to
30,32,33,
36,37,38,
39,42 to
47
E 4 58 III 17 Nil Conjunctivitis,
Respiratory
di,~~se
F 4041 52 IV 28-33 Nil Infantile diarrhea
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1.3 VIRAL PARTICLE AND GENOME
The adenovirus particle is a non-enveloped icosahedron that is 65-80 nm in diameter
depending on the serotype (Lee et al., 1995). The icosahedral capsid is composed of 252
capsomeres, including 240 hexons and 12 pentons.. The 12 pentons occupy the vertices of the
virion, and a knobbed fiber projects from each of these vertices (reviewed in Horwitz, 199Gb).
The fiber is a trimeric protein composed of; (1) an amino-terminal tail, which tethers the fiber to
the virus via the penton base; (2) a shaft, which gives the fiber its long length; and (3) a carboxy-
terminal knob, which contains the domains for receptor binding as well as for trimerization
(reviewed in Kovesdi et al., 1997). The length of the fiber valies with the adenovirus serotype
(Russell, 1994). Each penton capsomere is sun"ounded by five hexons, and thus the name penton
is derived from this arrangement. Each hexon is similarly surrounded by six capsomeres
(reviewed in Horwitz, 199Gb).
The vilion is composed of a number of polypeptides (Figure 1). The hexon subunit is
composed of three molecules of polypeptide II (120 kDa) which are held together by
noncovalent interactions (reviewed in Horwitz, 199Gb). Polypeptides VI (24 kDa), VIII (13
kDa), and IX (12 kDa) are associated with the hexon, and likely playa role in formation of the
virion's outer shell (reviewed in Doerfler, 1994). Polypeptide IlIa (66 kDa) is associated with
the hexons that are in direct contact with pentons. Each penton subunit is formed by five
molecules of polypeptide III (85 kDa), and the associated fiber is known to be composed of three
molecules of polypeptide N (62 kDa) (reviewed in Horwitz, 199Gb). Polypeptides V (48.5 kDa)
and VII (18.5 kDa) are associated with the viral DNA in the core structure and are very rich in
arginine, which neutralizes many of the negative charges on the DNA (Levy et al., 1994). Also
residing within the core is a 55 kDa terminal protein (TP), which is covalently linked to the viral
DNA and plays a role in the initiation of DNA replication. Another core protein is the Jl protein
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(4 kDa), which is lich in arginine and histidine, but cun4ently its function is unknown
(reviewed in Horwitz, 1990b).
Virion Polypeptide Structure
,...---11 (hexon)
III (penton)
Outer Shell
Ilia
~_ IV (fiber)
• .. •• M FP1
~;""-"':'P'.
. FP2
~~""'.~(<c:r--...,----.-- V (core protein)
Core
VII (core protein)
VIII ]
IX Outer Shelt
VI
Figure 1. A schematic diagran1 of an adenovirus palticle (reproduced from Doerfler, 1994).
Adenoviral DNA is linear and double-stranded, and has a size of 20 to 24 X 106 Da
depending on the serotype (Levy et al., 1994). The Ad DNA is approximately 11 Jlrn in length
or 36 kbp, and has inverted terminal repeats of 100- to 140- base pairs in length, again depending
on the serotype (reviewed in Horwitz, 1990b). These terminal repeats allow the DNA, when
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single-stranded, to form panhandle-shaped molecules (Levy et al., 1994). The GC content of
the DNA also varies with serotype, and is usually the highest for the most oncogenic serotypes.
The DNA also has the unique feature of a 55-kDa terminal protein covalently linked to dCMP at
each 5' end of the linear genome, which is involved in DNA replication (reviewed in Horwitz,
1990b).
1.4 VIRAL LIFE CYCLE
1.4.1 Virus Entry
Adenoviral entry into host cells is both efficient and rapid, with about 40% of bound
virus pa11icles able to release their DNA inside the cell (Greber et al., 1993). Adenoviruses are
known to enter their host cell by receptor mediated endocytosis, which ultimately results in the
delivery of the viral DNA to the host nucleus. Initially the fiber attaches to a receptor on the
surface of the host cell, and two cellular receptors for the fiber have been reported. One receptor
is termed the coxsackie and adenovirus receptor (CAR) because it functions as a receptor for
both adenovirus and coxsackie VilUS, and it contains two immunoglobulin domains (Bergelson et
al., 1997; Tomko et al., 1997). It has recently been shown that the IgV domain is necessary and
sufficient for binding, and no additional membrane components are required to confer high-
affinity binding to the Ad5 fiber knob (Kirby et al., 2000). The a2 domain of major
histocompatibility complex (MHC) class I has also been reported to mediate adenovirus
attachment via the fiber (Hong et al., 1997), however its role remains uncertain. The secondary
cell surface receptor has been identified as the vitronectin binding integrins, which bind to the
penton base of the virus and help to mediate the endocytosis (Wickham et al., 1993). After
binding to the receptors, the viruses are intelnalized via receptor-mediated endocytosis in
clathrin-coated pits. In these endosomes, the pH falls to 5.5, leading to the rupture of the
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endosome and the release of the virion into the cytoplasm (reviewed in Lee et al., 1995).
Adenoviruses undergo multiple sequential uncoating steps as they move from the cell surface to
the nuclear membrane (Figure 2). First, the fiber and polypeptide IlIa dissociate 10-12 min after
penetration, and the penton base is lost 3-5 min later. Next, the proteins linking the DNA to the
inside surface of the capsid are degraded or shed, including proteins VI and VIII. Lastly, the
capsid stabilizing minor proteins (IX, IlIa) are lost in endosomes. The uncoating process starts
immediately upon endocytic uptake, and results with the entrance of dissociated hexon proteins
and DNA into the nucleus (Greber et al., 1993).
!l;lJ0ft8r EnvtllOJ;Je
p(}r~ c~~
\J
Figure 2. Sequential steps involved in the uncoating of adenoviruses during cell entry
(reproduced from Greber et al., 1993).
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1.4.2 Early Gene Expression
The adenovirus replicative cycle is divided into early and late phases, with the early
phase occuning before the onset of viral DNA replication, and the late phase occurring after viral
DNA replication begins. Early cytoplasmic mRNAs are complementary to seven noncontiguous
regions on the viral DNA, starting from six different promoters. The early transcripts are divided
into "immediate early" (EIA), "delayed early" (EIB, E2A, E2B, E3 and E4), and "intermediate"
(IVa2, IX) (reviewed in Horwitz, 199Gb). Each region appears to contain a group of genes
coding for proteins having related functions (reviewed in Lee et al., 1995). The genes are
transcribed by the host's DNA-dependent RNA polymerase II (reviewed in Doerfler, 1994).
When considering the double-stranded linear genome of adenoviruses, the upper strand is termed
the right or right-transcribed strand, while the lower is the left or left-transclibed strand. The
light strand contains the E1 region at 1.3-11.2 map units and the E3 region from 76.6-86.2 map
units. The left strand contains the E4 region at 96.8-91.3 map units, the E2A region from 67.9-
61.5 map units and the E2B region from 29-14.2 map units (Figure 3) (reviewed in Horwitz,
199Gb).
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Figure 3. Transcription and translation map of adenovirus type 2 (reproduced from Horwitz,
199Gb).
Early Region 1 (El)
The E1A region of the adenovirus (1.3-4.5 map units) codes for more than SIX
polypeptides ranging from 38-51 kDa, with the two main proteins being 289 and 243 amino
acids long. The variety of resulting proteins alise from posttranslational modifications such as
phosphorylation (reviewed in Horwitz, 1990b). The E1A gene is the first to be transclibed in
productive infections, and its transcription does not depend on the action of any other viral gene
products (Nevins et aI., 1979). The E1A proteins increase E1A gene transcription to high levels
(Osbourne et al., 1984), and also stimulate the promoter activities of other viral genes including
the promoters for the E1B, E2A, E3 and E4 early genes as well as the major late promoter
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(Winberg and Shenk, 1985). EIA proteins have also been found to stimulate transcliption
from non-viral promoters (reviewed in Berk, 1986).
The EIA region is critical in adenovilus transformation, and is required for the
immortalization of cells in tissue culture (reviewed in Horwitz, 1990b). Complete
transformation of rodent cells requires functions encoded in both EIA and E1B; however,
transfection of cells with EIA alone can result in a cell with a pa11ially transformed phenotype
(Houweling et al., 1980; Gallimore et al., 1985). These cells have the potential to replicate
indefinitely in media with serum, but do not display the morphological features or high
saturation densities of cells transformed by both EIA and E1B (Berk, 1986). The domains in
EIA required for transformation include the E1A N terminus and the two regions conserved
between the various Ad serotypes, CR1 (Conserved region 1; amino acids 41-80) and CR2
(amino acids 121-139). These regions have been found to interact with a number of cellular
proteins including the product of the retinoblastoma locus (Rb), pl05. pRB and related proteins
(pl0? and p130) form complexes with the transcription factor E2F, that are disrupted by the
binding of EIA to Rb. Release of the transcriptionally active E2F can stimulate cellular DNA
synthesis in quiescent cells, and lead to cell immortilization (reviewed in Wong and Ziff, 1994).
A third conserved region (CR3; amino acids 140-188) is also present in the EIA region, and it is
essential for trans-activation of other virus transcliptional units (Kitchingman, 1993).
The EIA proteins are also responsible for both p53-dependent and p53-independent
apoptosis. The 243-residue EIA protein causes an increase in the level of the cellular tumor
suppressor gene p53, and induction of p53-dependent apoptosis. It is thought that the
accumulation of p53 is induced by the induction of unscheduled DNA synthesis by EIA
proteins, and that increased levels of p53 then activate cell death pathways (Querida et al.,
1997). In addition to these functions, the 289 and 243 amino acid proteins also induce sensitivity
to tumor necrosis factor a (TNF-a). TNF-a initiates a programmed cell death response in
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transformed cells which produces DNA fragmentation and cytolysis. Thus E1A is also
capable of inducing p53-indepepndent apoptosis (White et al., 1992).
The EIB region is located from 4.6 to 11.2 map units and codes for 2 major proteins of
19kDa and 55 kDa. In addition, EIB is predicted to code for at least three other polypeptides of
156, 93 and 84 residues (Takayesu et al., 1994). This region of the Ad genome also plays an
important role in transformation, specifically the 19 kDa and 55 kDa proteins. As previously
stated, the EIA gene alone can immortalize rat cells (Houwelling et al., 1980); however,
complete, high efficiency transformation requires that the EIB gene be co-expressed with EIA
(Barker and Berk, 1987). EIB gene products transform immortalized cells in a way that permits
growth to high saturation densities, and allows for the formation of tumors in
immunocompromised animals (Kitchingham, 1994). The expression of either EIB product
allows E1A-dependent cell transformation to occur, although the expression of both proteins
results in much higher transformation efficiencies (Querido et al., 1997). The 19 kDa protein
appears to protect against programmed cell death induced as a consequence of disruption of
growth control pathways by EIA (Takayesu et al., 1994). It appears that the 19kDa protein
adopts a Bcl2-like role, thus inhibiting apoptosis and DNA degradation (Grand et al., 1996). The
EIB 55 kDa protein has been found to bind to the p53 tumor suppresser protein, which may help
to control the cell cycle and transformation (Querido et al., 1997). The 19 kDa protein also has
trans-activating functions for EIA, EIB, E2, E3 and E4 as well as for the cellular heat shock
protein promoter (reviewed in Horwitz, 1990b). Furthermore, the EIB 55 kDa protein has been
found to interact with an early region 4 (E4) 25 kDa protein to allow efficient synthesis of viral
DNA, to support expression of late viral genes, and to aid in host-cell shutoff (reviewed in
Horwitz, 1990b).
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Early Region 2 (E2)
The E2A region (67.9-61.5 map units) codes for a single-stranded DNA binding protein
(DBP) which is heavily phosphorylated. This 72 kDa DBP is required for DNA replication both
in vivo and in vitro (reviewed in Horwitz, 1990b). In addition, the DBP is also involved in other
functions including repression of E4 transcliption, mRNA stability (Babich and Nevins, 1981),
assembly of virus particles (Nicholas et al., 1983), transformation (Ginsberg et al., 1974) and
host range function (Klessig and Grodzicker, 1979). The E2B region codes for the precursor to
the terminal protein (pTP), which is an 80 kDa polypeptide that is cleaved in the process of viral
assembly to the covalently linked 55 kDa terminal protein (Chalberg and Kelly, 1981). The
E2B region also codes for a 140 kDa Ad DNA polymerase, which plays an important role in
DNA replication (reviewed in Horwitz, 1990b). The E2 promoter is transactivated by both the
E1A protein, as well as the E4 6/7 protein (Swaminathan and Thimmapaya, 1996).
Early Region 3 (E3)
The E3 region is located at 76.6-82.6 map units, and about nine overlapping mRNAs are
expressed by alternative processing of a common pre-mRNA that initiates from the E3 promoter
(Chow et al., 1979). The series of open reading frames in the E3 region code for proteins that
modulate host functions in response to adenoviral infection (reviewed in Horwitz, 1990b). Of
the six identified E3 proteins, the functions of four are known. The 19 kDa glycoprotein
encoded by the E3 region has been shown to form a complex with the class I antigens of the
MHC in the endoplasmic reticulum, thereby blocking the transport of the class I antigens to the
cellular surface and thus protecting infected cells from lysis by cytotoxic T cells (Mahr and
Gooding, 1999). The 14.7 kDa proteins and 10.4 kDa / 14.5 kDa (Rilla and ~) proteins prevent
lysis of adenovirus infected cells by TNF, counteracting the sensitivity to TNF cytolysis that the
E1A gene products produce. The 10.4 kDa / 14.5 kDa proteins also stimulate the internalization
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and processing of the receptor for epidermal growth factor, thus activating the cell and
sUITounding cells to become efficient factories for virus replication (Wold and Gooding, 1991).
Early Region 4 (E4)
The E4 region is located from 96.8-91.3 map units on the left strand. Primary transcripts
from the E4 promoter are differentially spliced to give lise to at least 18 distinct mRNAs, which
are predicted to encode for ·seven different polypeptides (Leppard, 1997). E40rf3 and E40rf6
playa role in the control of alternative splicing of the major late tripartite leader during lytic viral
growth. The products of E40rf3 and E40rf6 appear to have redundant activities during Ad
infection, and expression of either one is sufficient to support wild-type levels of virus
production (Shtrichman and Kleinberger, 1998). E40rf6 is involved in host shutoff and transport
of viral late mRNAs to the cytoplasm, following complex formation with the EIB 55 kDa
polypeptide (Marcellus et al., 1998). E40rf6 also binds to p53, to block p53~mediated
transcriptional activation, to block p53-mediated apoptosis, and to enhance transformation by the
E1 region (Shtrichman and Kleinberger, 1998). E40rf6/7 binds as a homodimer to transcription
factor E2F to promote E2 promoter activity by ensuring correct spacing and orientation
(Marcellus et al., 1998). The E40rfl gene encodes a transforming protein, while the E40rf4
protein regulates protein phosphorylation in the infected cell by binding to protein phosphatase
(PP) 2A (Leppard, 1997). Little is known about the functions of the E40rf2 or E40rf3/4 proteins.
1.4.3 Late Gene Expression
As previously stated, the late phase of the adenoviral life cycle begins with the initiation
of viral DNA replication. The switch from the early to late phases is a~~omplex event that has
not yet been fully explained; however, some evidence indicates that some of the controls are cis-
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acting. There is no distinct division between the early and the late phases, as some late
proteins are made early and some early proteins are made late. L2 and L3 transcripts have been
found early, while the E2A mRNA and its polypeptide product the DBP are made both early and
late (reviewed in Horwitz, 1990b). Synthesis of the late transcript begins at 16.45 map units and
elongation occurs to approximately 99 map units. Transcliption of the late region is under
control of the major late promoter, and five major families of proteins (LI-L5) are produced
through extensive splicing of the late transcript (reviewed in Lee et al., 1995). Within each
family the mRNAs overlap in a staggered fashion, shaling the same 3' terminus but differing at
their 5' termini (Miller et at, 1980). Most of the late proteins are structural viral proteins or their
precursors. Late region 1 encodes the 52, 55 kDa polypeptide pair, and polypeptide IlIa. Late
region 2 codes for three proteins, polypeptides III, pVII and V, while late region 3 encodes for
polypeptides II and pVI. Late region 4 encodes for the 100 kDa protein, the 33 kDa protein, and
pVIII. Lastly, late region 5 encodes for the fiber protein, protein VI (Miller et al., 1980). Two
small RNAs are also synthesized from the adenoviral templates, but differ from mRNA in that
they are synthesized by RNA polymerase III and they do not code for polypeptides. These virus-
associated (VA) RNAs are 155 nucleotides long, and appear to control the rate. of translation of
the late polypeptides (reviewed in Horwitz, 1990b).
1.4.4 DNA Replication
Adenovirus DNA sequences begin to appear in large amounts at about 5 hours
postinfection (Levy et al., 1994). Ad DNA replication has been studied both in vivo and in
vitro, including an in vitro system that can initiate and elongate exogenous adenovirus templates
(Chalberg and Kelly, 1979). AdS possess an ITR that is 103 bp long and is located at either end
of the genome. The ITR contains the replication oligin of the viral DNA, and the most terminal
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51 bp sequence of the ITR is sufficient for maximal initiation of DNA replication (Temperley
and Hay, 1992). Thus the origin of replication is at the end of the genome, and either end of the
molecule can be used for initiation (Lichy et al., 1981). Ad DNA replication is
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semiconservative, and each strand elongates in a continuous 5' --+ 3' direction (reviewed in
Horwitz, 199Gb; Levy et al., 1994). The replication has been proposed to occur in two separate
ways, termed Type I replication and Type II replication (Figure 4). In Type I replication, strand
elongation occurs from duplex DNA with strand displacement, in a modified version of rolling-
circle replication. Initiation of this type of replication can begin at either end of the molecule;
however, reinitiation will always occur at the same end as the first round. In Type II replication,
replication occurs from a single-stranded template, likely the panhandle molecule that is formed
from single stranded molecules of the Ad genome as a result of the terminal redundancies
(Horwitz, 199Gb).
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Figure 4. Proposed models for adenoviral DNA replication (reproduced from Levy, 1994)
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Adenoviral DNA replication requires three virus coded polypeptides and four host
proteins. The 80 kDa pTP is the primer for DNA replication (Lichy et al., 1981). DNA
replication is initiated by the first deoxycytidyl triphosphate (dCTP) becoming esterified via its
5/ phosphate group to the ~-hydroxyl of a serine in the pTP. This pTP-eMP complex allows the
free 3/-OH group in the cytidyl residue to be used as the primer for the growing DNA chain
(Doerfler, 1994). The Ad DBP binds to the pTP and the terminal 18 bp of the Ad genome to
complete the initiation complex (Yoshida et al., 1995). During the initial phases of DNA
replication, the 80 kDa pTP is cleaved to the 55 kDa TP (reviewed in Horwitz, 1990b; Doerfler,
1994). The 140 kDa DNA polymerase is the other viral polypeptide required for DNA
replication (reviewed in Horwitz, 1990b; Levy et al., 1994). The host protein nuclear factor I
(NFl) is a polypeptide whose weight is between 47 and 160 kDa, and this protein binds to DNA
sites near the origin of replication and is required for initiation and elongation. NFII is a 30 kDa
complex of two polypeptides, which are 15 kDa and 17kDa. This is a type I topoisomerase that
is required for full elongation late in the process of DNA replication. NFIII is a DNA binding
protein that recognizes a sequence of the Ad genome 36-54 nucleotides from the origin of
replication, and enhances activity of the origin. ORP A also acts near the origin of replication
and binds within the first 12 nucleotides of the Ad genome, also assisting in replication
(reviewed in Horwitz, 1990b).
1.4.5 Assembly of Virions
Viral assembly occurs in the nucleus of the infected cell, but begins in the cytoplasm.
Initially, single polypeptides are assembled into capsomeres in the cytoplasm. The hexons are
formed upon trimerization of hexon monomers, aided by a 100 kDa scaffold protein. The
pentons are also formed, complete with the fiber attached. The hexon capsomeres then self-
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assemble into empty structures which are known as the "light intermediate" capsids. This
capsid contains a number of polypeptides, including 50 kDa and 39 kDa polypeptides, which act
as scaffold proteins in the formation of the capsid (reviewed in Horwitz, 1990b). It has then
been assumed that DNA enters the capsid through an opening at one of the vertices, after the
capsid has been transported to the nucleus. Virions then accumulate in the nucleus, and are
eventually released upon lysis of the cell (Levy et al., 1994). Occasionally, some adenoviruses
of group B are packaged defectively, leading to viruses which contain incomplete genomes
which are referred to as defective particles (reviewed in Horwitz, 1990b).
1.5 GENE THERAPY
Gene therapy basically consists of the introduction of nucleic acid into the cells of a
patient in order to use tIle expression of that nucleic acid for therapeutic benefit for the individual
(reviewed in Morgan and Anderson, 1993; Smith, 1995). There are two different systems that
can be used to introduce foreign genetic information into a patient. In the ex vivo method, target
cells taken from a patient are genetically modified in a laboratory and then reintroduced into the
patient to permit the in vivo expression of the gene of interest (reviewed in Brody and Crystal,
1994). In the in vivo method or the direct gene transfer method, the gene is directly delivered to
the cell without the need for ex vivo manipulations. Direct gene transfer can be carried out by
injection of naked plasmid DNA, liposome-encapsulated DNA, synthetic vectors linking foreign
genetic material to ligands that specifically bind to cell surface receptors, or by using viral-based
vectors that ca114 Ythe gene of interest (reviewed in Haddada et al., 1995). Initially, retroviruses
were the viral vehicle of choice for gene therapy, due to the virus's ability to integrate its genetic
material directly into the hosts chromosome resulting in a high efficiency of gene transfer into
replicating cells (reviewed in Morgan and Anderson, 1993). However, there are a number of
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disadvantages to retroviral vectors, including the difficulty involved with inserting large
pieces of DNA into these vectors, the fact that most retroviruses are unable to infect non-dividing
cells, and the risk associated with integration into the genome, including insertional mutagenesis
(reviewed in Weatherall, 1995). Attention is now tUlning to other viruses, including
adenoviruses, as gene delivery vehicles.
1.6 ADENOVIRUSES AS GENE THERAPY VECTORS
Adenoviruses have a number of advantages that make them attractive for use in gene
therapy. First and foremost, adenoviral vectors are safe. Live oral adenovirus vaccines have
been administered to over 10 million army recruits over the last 20 years with no detectable
forms of toxicity encountered (Rubin and Rorke, 1988). Also, the adenoviruses that are most
commonly used to make vectors are Ad2 and Ad5, and these strains do not cause tumors in
rodents, and cause only mild respiratory infections in humans (reviewed in Kremer and
PelTicaudet, 1995). Furthermore, adenoviruses can accept large foreign DNA inserts; they can
infect dividing as well as postmitotic cells; they can be concentrated to very high titers (reviewed
in Haddada et al., 1995); and they rarely integrate into the host genome, therefore having little
chance to result in insertional mutagenesis (reviewed in Kremer and Perricaudet, 1995). Of the
400 CUITent ongoing human gene therapy clinical t11als, more than 27% utilize adenovilus
vectors (AdVs; Wiley, Gene Therapy Website www.wiley.co.uk/genetherapy).
1.6.1 First-, Second-, and Third-Generation Adenovirus Vectors
As stated, adenoviral vectors are usually generated from the Ad2 and Ad5 strains, which
have genomes of approximately 35 kbp. The maximum amount of DNA that can be packaged
into the vi110ns is approximately 105-106% of the wild-type genome, or about 2 kbp of extra
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DNA (Ghosh-Choudhury et al., 1987). In order to allow for larger inserts into the genome, it
is necessary to delete viral DNA sequences, and then supply these lost gene functions in trans by
a helper cell line. The most common deletions remove up to 3.2 kbp in the E1 region and over 2
kbp in the E3 region of the genome, leading to vectors which can accept inselis of up to 7 kbp
(Graham and Prevec, 1991). These are referred to as first-generation Ad vectors. Because the
El region is essential for replication of the virus, vectors with the El region deleted are termed
replication deficient. These vectors must be propagated in 293 cells, a cell line transformed by
Ad5 DNA which contains and expresses the left end of the genome (Graham et al., 1977). The
E3 region is nonessential for replication of adenoviruses in cultured cells, and thus these
functions are not necessary to supply in trans. E1 deletions must not extend into the E1 region
containing the coding sequence for protein IX, which is essential for packaging of the viral
genome (Ghosh-Choudhury et al., 1987). In order to allow for the insertion of larger genes, and
to overcome some of the problems associated with first-generation Ad vectors such as transient
gene expression and safety concerns (see section 1.6.5), researchers have developed second and
third-generation Ad vectors.
Second-generation Ad vectors involve deleting additional genes from the Ad genome.
Generally, these vectors must be propagated and packaged in complementing cell lines that
supply the missing gene functions in trans. Ad vectors containing deletions in the E1 and E3
regions, along with a deletion of the Ad polymerase (E2B) gene have been developed
(Amalfitano et al., 1998). Complementary cell lines have been produced to generate Ad vectors
with deletions in the E1, E4 and pIX regions (Krougliak and Graham, 1995), or just the E1 and
E4 regions alone (Wang et al., 1995; Yeh et al., 1996). Deletions have also been made in the
E2A and E4 regions (Lusky et al., 1998), and the preterminal protein has been deleted from
some Ad vectors (Schaack et aI, 1996). The rationale for these second-generation Ad vectors
was that safety should be improved due to the further disabling of Ad replication, while
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increasing the amount of space available for the insertion of foreign genes. Researchers are
cUITently developing "gutless" vectors which contain only the inverted terminal repeats and
packaging sequences around the transgene, with all the necessary viral genes being supplied in
trans by a helper virus (Fisher et al., 1996; Chen et al., 1997; Schiedner et al., 1998). These
third-generation vectors can package 30 kbp of foreign DNA and contain' no viral genes;
however, their large-scale production remains a challenge (reviewed in Qualikene et al., 2000).
1.6.2 Adenovirus Vectors and Cystic Fibrosis Gene Therapy
Adenoviral vectors have been extensively studied for their use in treating cystic
fibrosis (CP). CF is a common, severe, autosomal, recessive genetic disease, which is caused by
dysfunction of an epithelial cell surface cAMP (cyclic adenosine monophosphate) activated
chloride channel. A rise in cAMP levels within the cells causes increased chloride secretion
through the CFTR (cystic fibrosis transmembrane conductance regulator) channel into the lumen,
resulting in a variety of effects for CF individuals including accumulation of mucus in the lungs
and gastrointestinal tract (Colledge and Evans, 1995). Cystic fibrosis is a disease that is an
attractive target for gene therapy because the gene required (CFTR) is well characterized and
only low-level expression is required. Adenoviral vectors have a number of characteristics that
make them suitable for CF gene therapy, including the ability of Ad vectors to accommodate the
4.5 kbp human CFTR cDNA, the natural tropism of Ad for respiratory epithelium (Crystal et al.,
1994), and the fact that they will efficiently infect non-replicating epithelial cells (Colledge and
Evans, 1995). The majority of adenoviral vectors used for CF gene therapy have deletions in the
E1 region, rendeling them replication deficient. Initially, studies were done on nonhuman
primates to study the effect of CFTR transfer to the lungs with adenoviral vectors (Engelhardt et
al., 1993). Initial reports of use with humans showed that the administration of AdCFTR to the
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nasal and bronchial epithelium could con"ect the defective chloride channel for a short time
(Zabner et al., 1993; Crystal et aI, 1994). However, high doses of the vector could result in
adverse reactions including headache, fatigue, and fever, possibly due to release of interleukin-6
(IL-6), a cytokine known to induce these conditions (McElvany and Crystal, 1995). Improved
Ad vectors to treat CF are continually being developed (Zuckerman et al., 1999; Bigger and
Coutelle, 2001; Perricone et al., 2001).
1.6.3 Adenovirus Vectors and Cancer Gene Therapy
As more information about the causes of cancer is obtained, and the genes associated
with cancer are discovered, the use of Ads for cancer gene therapy increases. While long-term
expression of the genes of interest is essential for non-malignant tllerapies, such as that for cystic
fibrosis, long-term expression is unnecessary for cancer gene therapy (Weitzmann et al., 1996).
Furthermore, a number of the vectors used in cancer gene therapy are replication competent,
which is again different from gene therapy for other diseases. The E1 gene can be inserted into a
first-generation virus under the control of a tumor-specific promoter, and theoretically, injection
of this virus should allow for replication only in the tumor but not in the surrounding normal
cells. This type of vector could be used to kill tumors directly by lysis, or by delivery of a
'suicide gene' such as the herpes-simplex-virus thymidine kinase gene (HSV-tk) , which can kill
infected and bystander cells following treatment with the pro-drug Gancyclovir (reviewed in
Robbins et al., 1998). A number of different groups of researchers are investigating the use of
Ad vectors for suicide gene therapy of cancer (Wildner et aI., 1999; Lee et aI., 2001). A phase I
clinical trial for the treatment of prostate cancer using a replication-deficient Ad vector
containing the HSV-tk gene has been completed (Shalev et al., 2000). Suicide gene therapy
using Ad vectors appears to be very promising for the treatment of cancer (Freeman, 2000).
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Adenovirus vectors can also be used to deliver tumor supressor genes in order to
treat cancer (Wills et al., 1994; Schuler et al., 1998). Mutations of the tumor suppressor p53 are
the most common genetic alterations observed in human cancer, and loss of this p53 function
impairs cell cycle arrest as well as repair mechanisms involved in the response to DNA damage.
By supplying the p53 gene, local control of the disease can be observed (Schuler et al., 1998). A
number of clinical tlials involving Ad vectors and p53 genes are cUITently underway, including a
trial for metastatic malignant liver tumours (Habib et al., 1999), and a trial for the treatment of
bladder cancer (Kuball et al., 2002). Researchers continue to develop Ad vectors for the delivery
of the p53 gene (Morrissey et al., 2002). Furthermore, Ad vectors can be used to introduce
genes that result in stimulation of an immune response' to the tumor. This may include the
delivery of a valiety of cytokines, which have been shown to decrease tumor growth when
ectopically expressed on tumor cells or in their microenvironment. Some success has been seen
with the use of IL-2 for liver metastasis, and IL-12 for use in melanoma and breast cancer
clinical trials (reviewed in Weitzman et al., 1996).
1.6.4 Additional Applications for Adenovirus Vectors and Gene Therapy
In addition to their use in gene therapy for cystic fibrosis and cancer, adenoviral vectors
are also used for a number of other gene therapy applications. Adenoviral vectors have recently
been shown to be extremely efficient gene transfer vectors for liver-directed gene therapy (Raper
et al., 1998). Adenoviruses are being investigated for their potential use as gene vector systems
to treat a number of neurodegenerative diseases. Ad vectors encoding for superoxide dismutase,
tyrosine hydroxylase and GDNF are cUITently being investigated to treat Parkinson's disease,
and vector systems are also being developed to treat motor neuron diseases (Barkats et ai, 1998).
Adenovirus vectors are also being investigated for the treatment of hemophilia A. Hemophilia A
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is the most common inherited bleeding disorder, and is caused by a deficiency in coagulation
factor VIII (Balague et al., 2000). Replacement of the deficient factor with frequent intravenous
injections of plasma concentrates or recombinant proteins is the standard treatment for the
disease. Hemophilia is a good candidate for gene therapy treatment due to a number of reasons,
including the fact that there is a simple and well defined cause-and-effect relationship between
the protein deficiency and bleeding symptoms, and even 1% to 5% of the normal physiological
levels of the protein are therapeutic (Zhang et al., 1999). The liver is the site of factor VIII
production, and upon intravenous injection the Ad vectors concentrate in the liver, making Ad
vectors a promising system for the treatment of hemophilia A (Zhang et al., 1999). Using a
minimal adenovirus vector deleted of all viral sequences and containing the full-length human
factor VIII cDNA, researchers have been able to demonstrate the sustained high-level expression
of the factor and restoration of clotting activity in hemophilic mice (Balague et ai., 2000). These
results show the promise of gene therapy for hemophilia, and support further investigation and
clinical trials.
1.6.5 Problems with Adenovirus Vectors for Gene Therapy
1.6.5. 1 Transient Gene Expression
There are a number of problems associated with adenovirus vectors. The first major
drawback of the use of Ad vectors in gene therapy is that foreign gene expression is transient due
to death of target cells resulting from host cellular immune responses. Expression of a first-
generation adenovirus vector in the liver after intravenous administration can be extensive in the
first 1-3 days, but after 3 weeks expression can decrease by >90% (Worgall et ai., 1997). It has
been shown that cells carrying the recombinant viral genome express the transgene as desired;
however, low level expression of viral genes also occurs. This results in the presentation of viral
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proteins to the immune system, and the cells expressing these viral antigens are recognized by
antigen-specific cytotoxic T cells and eliminated (Yang et ai., 1994; Kaplan et ai., 1997;
Worgall et al., 1997). FUlihermore, the adenoviral infection can tligger a strong inflammatory
reaction affecting the patient's health, and also leading to the shut down of transgene expression
as a consequence of destruction of host cells (Barkats et ai., 1998).
In order to overcome these problems of transient gene expression, many researchers are
attempting to construct improved vectors, which consist of greater deletions in the viral genome
and thus have a decreased ability to express viral genes and less chance of being "recognized" by
the immune system. These are the second-generation Ad vectors (Amalfitano et ai., 1996;
Schaack et ai., 1996; Amalfitano et ai., 1998; Lusky et ai., 1998). It is the believed that deletion
of viral genes necessary for Ad genome replication should block viral DNA replication and
decrease viral protein production, resulting in a diminished immune response and extended
duration of foreign gene expression (Amalfitano et al., 1996). Using "gutless" vectors with no
viral genes at all, Chen et aI. (1997) have shown the stable expression of a transgene in mice
muscles for up to 84 days, and Schieder et al. (1998) have shown expression of a transgene in
mice for up to ten months. Recently, gutless Ad vectors have been shown to have improved
transgene expression in the central nervous system of rats as compared to first-generation
adenovirus vectors (Zou et ai., 2000), and gutless vectors expressing the human FYIII were
shown to display increased duration and levels of expression when compared to an analogous
early generation vector (Reddy et al., 2002). However, some contradictory results have been
reported showing that increased deletions in the adenoviral genome do not extend the in vivo
persistence of the transduced cells and do not reduce the antivilus immune response in mice
(Lusky et aI., 1998).
It has also been found that the expression of the E3 14.7K gene within the Ad vector can
help to prolong gene expression. Harrod et aI. (1998) found that a vector containing the E3
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14.7K gene resulted in increased transgene expression in the respiratory epithelium of mice
over a 21-day peliod as compared to an E1-E3-deleted Ad vector. The inclusion of the E3
region in an Ad vector used for arterial gene transfer was also found to reduce inflammation and
prolong gene expression (Wen et al., 2001).
1.6.5.2 Humorsllmmunity
In addition to the problems of cell-mediated immune responses to adenoviral vectors,
there is also the problem of humoral immunity which prevents adenovilus vector-mediated gene
expression upon initial administration or re-administration of the vector. Adenovirus type 5 is
commonly used for the construction of Ad vectors, and it also commonly infects humans. Thus
many adults have pre-existing neutralizing antibodies and cytotoxic T lymphocytes (CTL)
against adenoviruses (Schulick et cll., 1997). Injection of a recombinant adenovirus into these
individuals would be expected to produce a strong secondary immune response, resulting in
destruction of the cells (nan et al., 1998). This is also the problem that is encountered when a
repeat administration of an adenoviral vector is attempted, such as in the treatment of CF (Dong
et al., 1996; Kaplan et al., 1996). Repeated administration of an Ad vector encoding the CFTR
gene to patients with CF was shown to result in humoral immune responses (Zabner et al., 1996).
A number of methods to overcome the problem with humoral immunity have been
investigated. Because neutralizing antibodies directed against one adenovirus serotype do not
block infection by another adenovilus serotype, one approach to achieving successful repeat
administration is to alternate the serotype of the human adenovirus vector being used (Kovesdi et
al., 1997). It has also been shown that oral tolelization of rats to adenoviral antigens allows
repeated administration of adenoviral vectors (nan et al., 1998). Furthermore, it has been shown
that the inclusion of the E3 region in adenoviral vectors allows long-term gene expression and
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readministration in the liver (Ilan et al., 1997). Because the E3 region contains many genes
involved in the host immune response (gp19K, 14.7K), inclusion of this gene in vectors helps to
inhibit the antiviral humoral immune response. Lastly, some success has been achieved in
animal models through the use of immunosupressive drugs or monoclonal antibodies blocking
the T cell receptor (reviewed in Rasmussen et al., 1999).
Another method being used to overcome the problem of humoral immunity is to use
adenoviral vectors that are constructed from serotypes other than human. These adenoviruses are
attractive for their use in gene therapy because there is no pre-existing immunity to non-human
Ads in humans; thus, there will be no strong secondary immune responses upon administration.
One group of Ads that is being extensively studied is canine adenovirus type 2 (CAV-2)
(Klonjkowski et al., 1997). A CAV-2 E1-deleted vector was produced, and was shown to be
able to direct expression of a transgene in human and non-human cells in vitro (Klonjkowski et
al., 1997). Development of CAY vectors for use in human gene therapy, as well as their
characterization and comparison to human Ads continues (Kremer et al., 2000). Bovine
adenoviruses (BAVs) are also being investigated for their potential as gene therapy vectors.
BAV 2 and 3 are currently the most extensively studied strains of bovine adenovirus, and the
sequencing of the genomes has been completed, along with the identification of many key genes
within the genomes (Salmon et al., 1993; Salmon and Raj-Ahmad, 1994; Esford and Raj-
Ahmad, 1994; Ojkic et aI, 1997; Fitzgerald et al., 1997; Yagubi et aI, 1998). BAV3 has been
shown to infect human cells without showing growth or cytotoxic effects, and viral gene
expression was barely detectable (Rasmussen et al., 1999). Recently, a replication-deficient
chimpanzee adenovirus vector has been developed and tested in human cells (Farina et al.,
2001). Thus, a promising way to overcome the problem of Humoral immunity in human gene
thetrlpy is to use adenoviral vectors based on serbtypes other than human.
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1.6.5.3 Tissue Tropism
Although adenovirus vectors are extremely attractive for their use in gene therapy, they
tend to have promiscuous tissue tropism that leads to ectopic expression of the transgene. This
lack of tissue tropism severely limits the applicability of Ad vectors in the gene therapy of many
diseases. As previously stated, Ad tropism is determined by the interaction of the fiber and the
receptors on the surface of the host cells. Unfol1unately, the widespread distlibution of the CAR
receptor for Ad5 precludes the targeting of specific cell types (Douglas and CUliel, 1997). The
lack of tropism of Ad vectors results in a decrease in the efficiency of gene therapy due to
sequestration of the vector in non-target cells. In addition, the different receptors for the
different Ad serotypes are often unevenly distributed. Adenovirus receptor density among
tumour cell populations of the same histology has been hypothesized to influence transduction
efficiency and therapeutic results in gene therapy strategies. A 5-fold variation in Ad receptor
density was identified among head and neck squamous cell carcinoma cell lines (Li et al., 1999).
One way to overcome these problems is by creating chimelic fibers, in order to redirect
Ad vectors. A chimeric AdS/Ad3 fiber allowed for an Ad vector to be retargeted to the Ad3
receptor, and resulted in an increase of gene transfer into ovalian cancer cells as opposed to a
vector with an AdS fiber (Kanerva et al., 2002). One group has looked into a number of
approaches in order to modify the tropism of Ad vectors to accomplish targeted transduction of
muscle cells for Duchene muscular dystrophy. These included incorporating targeting ligands
into the adenovirus fiber, and creating chimeric Ad5/Ad3 fibers with altered receptor recognition
profiles (Douglas and Curiel, 1997). Ad vectors have also been redirected to the pulmonary
endothelium through the use of cationic liposomes and bispecific antibodies to endothelial cells
(Ma et al., 2002). Targeting has also been performed through the use of specific promoters that
will only be expressed in certain tissues. This strategy proved successful in the expression of a
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gene in the cardiac muscle under the control of cardiac-specific promoters (Griscelli et al.,
1998). Work is continuing in the area of Ad tropism and vector targeting to specific cells.
1.6.5.4 Replication Competent Adenoviruses
The last major problem associated with adenoviral vectors is the creation of replication
competent adenoviruses (RCA) through recombination events (Kremer and Pen4 icaudet, 1995).
The presence of replication competent recombinant adenoviruses is a safety risk for gene
therapy, because they can result in the mobilization and spread of the replication-defective vector
viruses, and also in significant tissue damage and pathogenicity (Fallaux et al., 1998).
Occasionally, this generation of RCA is the result of E1-complementation in trans by wild-type
adenovirus infections. This would be of particular concern for gene therapy involving cystic
fibrosis due to the need for the recombinant adenovirus to be administered to the respiratory
tract, the site that is naturally infected by wild-type adenoviruses. In an attempt to decrease the
likelihood of this event, Imler et all (1995) have produced a vector carrying the CFTR gene in
which a mutation was introduced in the cis-acting sequences that control the encapsidation of the
viral genome. The results of this mutation are that in the presence of the wild-type virus, the
DNA containing the wild-type encapsidation sequences are preferentially packaged, and the
recombinant virus will therefore be destroyed by the host immune response (Imler et al., 1995).
A more common way in which the recombinant adenoviral vectors become replication
competent is through recombination between the vector and the 293 packaging cell line
(Lochmuller et al., 1994; Hehir et all 1996; Zhu et al., 1999). In typical El deleted vectors, there
are at least 450 bp of homologous sequences in the vector and 293 cells at the left-hand side of
the transgene, and about 800 bp of homologous sequences at the light-hand side (Fallaux et al.,
1998). As a result of these homologous regions a dual recombination event can occur to the left
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and the right of the transgene, resulting in the loss of the transgene and acquirement by the
vector ofthe E1 region.
A number of different groups have used various approaches in order to overcome the
problem of RCA generation. Hehir et ale (1996) modified their adenoviral vectors by deleting or
rearranging the protein IX coding region, thereby greatly reducing the frequency of
recombination between the vector and the 293 cells. In addition to altering the backbone of the
vector to decrease the frequency of recombination, new helper cell lines can also be produced
along with matching vectors. Fallaux et al. (1998) have developed helper cell lines which
contain the Ad5 E1 region from bp 459-3510. They also developed matched Ad5 vectors, which
lack nucleotides 459-3510, thereby removing any overlapping sequences of homology and thus
preventing the generation of RCA by homologous recombination. A new cell line obtained by
transfection of primary human animocytes with plasmid DNA expressing the E1A and E1B
functions has also been produced. The generation of RCA is prevented in this cell line by
designing the transforming plasmid to lack sequence overlap with current adenoviral vectors
(Schiedner et al., 2000). A HeLa-based E1-expressing cell line with no homology 5' to E1 and
reduced homology 3' to E1 has been produced. This cell line has been shown to exclude the
emergence of RCA for over 20 passages of an E1-deficient vector (Gao et aI., 2000). An
additional HeLa-based cell line that expresses the E1 region of Ad5 has been developed, and was
also shown to not generate RCA (Kim et al., 2001).
1.6.5.5 The Death of Jesse Gelsinger
The problems with adenovirus vectors in gene therapy can best be exemplified by the
tragic death of 18-year-old Jesse Gelsinger. Four days after receiving a very high dose (3.8 x
1013 virus particles) of an Ad vector carrying the ornithine-transcarbamylase (OTC) gene to
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control his ammonia metabolism, Jesse Gelsinger died of multiple organ failure. He was the
first patient in a gene therapy trial to die of the therapy itself (Marshall, 1999). To this day, the
exact reason for Jesse's death is unclear. It was found that the Ad vector carrying the aTC gene
invaded not just the intended organ (the liver), but also many other organs including the spleen,
lung, thyroid, kidney, and brain. In spite of the massive dose of the vector that he received, only
1% of the transferred genes reached the target organ. This dissemination caused an activation of
innate immunity, followed by a systemic inflammatory response that resulted in his death
(Marshall, 1999). Recently, it has been suggested that perhaps the Ad virus used in the trial
induced a forceful response from the complement system, as a result of pre-existing antibodies
against adenoviruses. It has been proposed that a viral dose comparable to the level that Jesse
received may raise the concentration of a key component of the complement system to a level
that could start a damaging immune reaction (Bostanci, 2002). It is clear from this tragic event
that there are still many areas of gene therapy that are not fully understood, and that perhaps the
data acquired from animal trials can not always be directly applicable to human trials. However,
it does appear that the death of Jesse Gelsinger was unusual. Since 1999, a number of
documents have been compiled to assess the risk factors and safety of Ad vectors in human
subjects, and the results have been promising (Crystal et al., 2002; Harvey et al., 2002).
1.7 ADENOVIRUSES AS VACCINES
Although the stimulation of an immune response by a transgene is an obstacle for gene
therapy, it is exactly what is desired for vaccination. The purpose of a vaccine is to produce a
comprehensive immune response (antibody-mediated, cell-mediated and mucosal), such that a
subsequent infection with the virus will quickly be recognized and abolished. For vaccination, it
is usually only necessary to express the transgene long enough to stimulate an effective immune
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response (reviewed in Wilkinson and Borysiewicz, 1995). Furthermore, because the majolity
of viruses enter into their host via mucosal surfaces, the ideal vaccine should stimulate mucosal
immunity. This type of immunity is best induced by intranasal or oral delivery, and thus the
most effective vaccines would be designed for delivery by mucosal routes (Babiuk et a/., 1996).
Vaccines can be either live, inactivated or subunit vaccines (reviewed in Wilkinson and
Borysiewicz, 1995). A new generation of viral vaccines is now being investigated, which
involves the identification and isolation of the virulence factors of viruses and the proteins or
glycoproteins involved in inducing neutralizing antibodies or cell mediated responses to the
viruses (Babiuk et at., 1996). Once these proteins and glycoproteins have been identified, they
can then be placed into various expression systems, including viral vectors. Adenoviruses have
great potential for their use as recombinant live viral vaccines for both animals and humans.
First, live adenovirus vaccines for Ad4 and Ad7 prepared in entelic-coated tablets have been
administered to millions of army recruits in the last 20 years and have proven to be safe (Rubin
and Rorke, 1988). Furthermore, Ad5 infections are usually not associated with serious illness,
and this is the strain from which most adenoviral vectors are constructed. Also, human
adenoviruses naturally infect the epithelial cells of the respiratory tract, indicating their ability to
induce mucosal immunity (Graham and Prevec, 1992). Thus, adenoviral vectors appear
attractive for use in developing vaccines for humans and for animals.
The adenoviral vectors used to produce these recombinant vaccines can be either
replication competent, or replication defective (reviewed in Wilkinson and Borysiewicz, 1995).
Some replication-competent Ad5 vectors carrying HSV, VSV, or rabies glycoprotein-coding
sequences in the E3 region have been shown to raise neutralizing antibodies in rhesus monkeys,
cows, pigs, dogs, foxes, striped skunks, raccoons and mice (Graham and Prevec, 1992).
Furthermore, since Ad vectors expressing genes from HPV, HIV, CMV and RSV generate
immune responses in animals, they are currently being tested in humans (reviewed in Wilkinson
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and Borysiewicz, 1995). Replication defective adenovirus vectors with deletions in the E1
region have been used to express a pseudorabies glycoprotein, a flavivirus nonstructural protein,
EBV gp220/360 and the measles virus nucleocapsid, all resulting in an immune response in
animals (reviewed in Wilkinson and Borysiewicz, 1995; Stephenson, 1998). A replication-
deficient Ad vector expressing the envelope glycoprotein gene (env) of HIV-1 has been
constlucted, and was shown to induce both a humoral and CTL response in mice (Bruce et al.,
1999). Recently, an AdS vector was shown to be the most effective vaccine vector delivery
system for HIV infections in humans, upon comparison to other potential vaccines (Shiver et al.,
2002). These results are promising for the development of recombinant adenoviral vaccines for
man.
. In addition to the use of adenovirus vectors for human vaccines, they are also being
investigated for their use in developing vaccines for animals. Foot-and-mouth disease virus
(FMDV) is an RNA virus which causes a highly contagious disease affecting cloven-hoofed
animals including cattle, pigs and sheep. Vaccination plays a large role in the control of the
disease, and recently a replication-defective AdS vector has been developed for use as a sub-unit
vaccine against FMDV (Mayr et al., 1999). This vector was found to induce the production of
neutralizing antibodies in animals, and thus may be used for vaccination against the disease.
Recombinant BAVs also have considerable potential to provide a protective mucosal immune
response in animals, because BAVs naturally infect the respiratory and gastrointestinal tract of
cattle (Mittal et al., 1995). The first bovine adenovirus expression vector was generated in 1995
(Mittal et al., 1995), and was based on BAV3. The vector was non-defective and contained a
696 bp deletion in the E3 region, into which the firefly luciferase gene was inserted. The vector
was shown to infect cells and express luciferase, thereby proving that the BAV3 E3 gene
products are not necessary for virus growth in cultured cells, and can therefore be replaced with
foreign genes. Mittal et al. (1996) have also shown that this vector produces pulmonary lesions
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in cotton rats similar to those produced by the wildtype BAV3 virus. This finding further
verifies the idea that BAV vectors have excellent potential for the development of recombinant
vaccines for cattle, and may also be suitable as vectors for human gene therapy. Recently,
BAV-3 vectors expressing a bovine herpesvirus-1 glycoprotein were shown to induce protective
immune responses in calves (Zakhartchouk et al., 1999; Reddy et al., 2000).
1.8 OBJECTIVES OF PROJECT
The most commonly used packaging cell line for replication deficient hUll1an
adenoviruses is the 293 cell line (Graham et al., 1977). However, this cell line has been shown
to lead to the production of replication competent adenoviruses through the process of
homologous recombination between the vector and the cell line. Thus the objective of this
project was to produce a cassette that was used to modify the 293 cell line through the process of
homologous recombination. The modification involved the removal of the first 380 bp of the
adenoviral genome from the 293 cells, such that these sequences that serve as a region of
homology on the left-hand side of the transgene in the vector would be removed from the cell
line, and replication competent adenovirus formation will be prevented. In order to reach this
objective, the following tasks were undertaken:
1) Identification and cloning of the left cellular-viral junction in 293 cells.
2) Engineering the plasmid that was used to modify 293 cells.
3) Transfection of 293 cells with the constructed plasmid, identification of the cells that had
undergone homologous recombination, and characterization of the new cell line.
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2. MATERIALS AND METHODS
2.1 BACTERIAL STRAIN
The bacterial strain used for cloning and propagation of plasmid DNA was Escherichia
coli DH5a, with the genotype (F, <p80, 8lacZ, ~M15, i1(lacZYA-argF) , U169, deaR, recAl,
endAI, hsdRI7(rk-, mk+), phaA, supE44, thi-I, A-,gryA96, relA1) (Woodcock et al., 1989).
Bacterial cultures were grown in sterile LUlia-Bertani broth (LB; 100/0 bacto-tryptone, 50/0 bacto-
yeast extract, 100/0 NaCI, 4N NaOH to pH 7.0) ovelnight at 37°C. For storage, cells were frozen
in 150/0 glycerol (3 ml of 500/0 glycerol added to 7 ml of cells), and stored at -80°C for long term
maintenance. To propagate culture from frozen stocks, cells were thawed and streaked onto agar
plates using a sterile inoculating loop. Single colonies could be isolated from these plates, and
the plates could be stored short term at 4°C.
2.2 PREPARATION OF COMPETENT CELLS
Competent bacterial cells were prepared according to Sambrook et ale (1989). The E.
coli was first streaked on agar plates to allow for the isolation of a single colony. Half of a
colony was picked and inoculated into 2 ml of LB and the other half of the colony was
inoculated into 2 m1 of LB supplemented with 100 ~g/ml ampicillin and grown overnight in a
37°C shaker bath. If the colony inoculated into LB with ampicillin showed no growth, then a
500 m1 flask of LB was inoculated with 2 ml of overnight culture from the LB tube and grown to
mid-log phase (O.D. 550 = 0.45-0.55). The cells were then placed on ice and centrifuged for 10
min at 3500 rpm at 4°C in a Beckman Avanti J25 centrifuge using a JA-14 rotor. The
supernatant was decanted, and the cells were resuspended in 20 ml of cold transformation buffer
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(75 mM CaCI2, 5 mM Tris, pH 7.6) and incubated ovelnight at 4°C. The next day the cells
were centrifuged again at 3500 rpm for 10 min at 4°C, the supelnatant was decanted, and the
cells were resuspended in 4 ml of cold transformation buffer and incubated on ice for 45
minutes. To store competent cells for subsequent use, 500/0 glycerol was added to the cells (3 ml
per 7 ml of cells), and 150 JlI aliquots were placed into sterile 1.5 ml Eppendorf tubes and stored
at -80°C for up to 3 months.
2.3 BACTERIAL TRANSFORMATIONS
Transformations were carried out as desclibed by Sambrook et ale (1989). Competent
cells were removed from storage in -80°C and placed on ice. Ligated DNA (usually 5 ~l) was
added to each tube, and the cells were incubated on ice for 30 minutes with gentle mixing of the
contents every 10 minutes. The cells were then heat shocked at 42°C for 45 seconds, put back
onto ice for 2 minutes, diluted with 850 JlI of LB and grown for 45 minutes in a slow 37°C
shaker. Following incubation, the cells were spread (150 J.lI per plate) on LB-agar plates
supplemented with either ampicillin or kanamycin. For the transformation of plasmids that were
to be plated on kanamycin plates, the incubation period in the 37°C shaker was extended to 90
minutes. The plates were then incubated at 37°C overnight in order to obtain colonies.
2.4 SMALL SCALE PLASMID ISOLATION
The method used for small scale plasmid isolation was based on the method of Sambrook
et ale (1989). Individual colonies were first picked from plates using stelile wooden sticks and
inoculated into 2 ml LB containing ampicillin. The cells were then grown at 37°C overnight,
and the next day 1.5 ml of culture was transfelTed into a stelile Eppendorf tube. The cells were
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then centrifuged for 30 seconds and the supeluatant was aspirated. The cells were then
resuspended in 200 J.ll of cell resuspension solution (50 mM Tris Hel (pH 7.5), 10 mM EDTA,
100 J.lg/ml RNase A) and vortexed well to resuspend the pellet. Next, 200 J.lI of cell lysis
solution (0.2 M NaOH, 1% SDS) was added to each tube, and the tubes were inverted for 1
minute in order to mix the contents. Subsequently, 200 JlI of neutralization solution (1.32 M K
acetate, pH 4.8) was added to each tube and again mixed for 1 minute. The tubes were then
centrifuged for 10 minutes at room temperature, and the supernatant was then transferred to a
new sterile tube, being careful not to include any of the pellet. Isopropanol (300 ~l) was then
added to the tubes and mixed to allow for precipitation of the DNA. The tubes were again
centrifuged for 10 minutes, and the supernatant was decanted and the tubes were air dried to
remove any traces of alcohol. Lastly, the DNA pellet was resuspended in 100 J.lI of TE buffer.
2.5 LARGE SCALE PLASMID ISOLATION
Large scale plasmid extraction and isolation is essentially the same as described above,
again being based on the methods of Sambrook et al. (1989). A pure colony was first picked
from a plate and grown overnight in 2 ml of LB with ampicillin at 37°C. The following day, a
500 ml flask of LB with ampicillin was inoculated with 1-2 ml of the oveluight culture and again
allowed to grow ovelnight at 37°C. Next, the 500 ml overnight culture was pelleted by
centrifugation at 5700 rpm for 10 minutes at 22-25°C in a Beckman Avanti J25 centrifuge using
a JA-14 rotor. The supelnatant was immediately decanted, and the cells were resuspended in 15
ml (per centlifuge tube) of cell resuspension solution. To aid in resuspension, the pellet was
manually disrupted using the pipette. Next, 15 ml of cell lysis solution was added to each tube,
and the contents were mixed gently by inversion until cell lysis was complete and the solution
became clear and viscous. Following this, 15 ml of neutralization solution was added to each
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tube, and the tubes were again mixed by inversion and then centlifuged at 9550 rpm for 15
minutes at 22-25°C. The supelnatant was then filtered through stelilized coffee filters into clean
centrifuge bottles, and then 22 ml of room temperature isopropanol was added to the supelnatant
and mixed by inversion. The tubes were then centrifuged at 9550 rpm for 15 minutes at 22-
25°C, the supernatant discarded and the DNA pellet was air dried at room temperature. Lastly,
the DNA was resuspended in 2 ml of TE buffer and aliquoted by 1 ml into 2 sterile Eppendorf
tubes.
2.6 CESIUM CHLORIDE GRADIENT CENTRIFUGATION
Ethidium bromide - cesium chloride gradient centrifugation (Sambrook et al., 1989) was
used to prepare high grade plasmid DNA for purposes such as transfection into mamnlalian cells.
Cesium chlolide was added to DNA suspended in TE buffer, such that the final density of the
solution was 1.57 - 1.59 g/ml. Subsequently, 500 J-li of ethidium bromide (10 mg/ml) was added
to the DNA, and the solution was transferred to Beckman Optiseal ultracentrifuge tubes. The
tubes were then centrifuged in a Beckman Optima XL-l OOK ultracentlifuge in a NVT65 rotor for
22 hours at 65,000 rpm and 22°C. After centlifugation, the red band containing the supercoiled
plasmid DNA was removed with a needle and syringe, and extracted several times with isoamyl
alcohol (saturated with CsCI and distilled water), to remove the EtBr.
DNA samples pUlified using the cesium chloride gradient technique were dialysed prior
to use in mammalian cell culture transfection. A 5 em piece of Spectra/Por® 7 (Spectrum
Laboratolies, Inc.) dialysis membrane tubing was boiled in distilled water for 15 minutes prior to
use. After the tubing had cooled, one end was clamped and the DNA was transferred into the
tube and then the other end was clamped. The dialysis tubing containing the DNA was then
placed into a 2L flask containing O.IX SSC buffer (15 mM NaCI, 1.5mM Na3C6Hs07.2H20) and
53
stirred at 4°C for 1 hour. The O.lX sse buffer was then changed, and the tubing and DNA
were stirred overnight at 4°C. The following morning the DNA was transferred to an Eppendorf
tube and the concentration determined.
2.7 DNA CONCENTRATION DETERMINATION
The DNA concentration was determined by measuling the absorbance at 260 nrn (Hitachi
V-2000 Spectrophotometer) and applying the following formula:
[DNA] = (A26o x dilution factor x 50) / 1000 ~g/~l
The pUlity of DNA was determined by measuling the absorbance of the sample at 260 nrn and
280 nrn. An OD260lOD280 of 1.8 to 2.0 was used to indicate a pure preparation.
2.8 DNA SEQUENCING
DNA sequencing was performed by Norgen Biotek Corp. (St. Catharines, ON), using a
Visible Genetics Inc. Long-Read Tower. Sequence alignments and comparisons were performed
using the BLAST software (Altschul et al., 1997), available through the National Center for
Biotechnology Information (http://www.ncbi.nlm.nih.gov).
2.9 RESTRICTION ENZYME DIGESTIONS
Restliction enzymes were used as specified by the manufacturer (New England Biolabs).
Typical reaction mixtures were 20 ~l in total volume and consisted of 1-2 J-lg of DNA, 2 III of
recommended lOX restriction enzyme buffer, 2J.ll of BSA for a final concentration of 0.01 Ilg/Ill
if required, and 1-10 units of enzyme. One unit of enzyme is defined as the amount of enzyme
required to digest lllg of ADNA in one hour at 37°C in a total reaction volume of 50 Ill. The
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total volume was then brought up to 20 1-11 with distilled, autoclaved water. Digestions were
generally left overnight at 37°C.
2.10 SHRIMP ALKALINE PHOSPHATASE
In order to prevent self-ligation and recirculization of plasmid DNA in a reaction mixture,
Sluimp Alkaline Phosphatase (SAP) (Boehringer Mannheim) was frequently used to remove the
5' phosphate groups from one of the DNA digestions. Generally, 30 J.11 of digested DNA
mixture, 6 J.11 of the lOX SAP buffer (0.5 M Tris-HCI, 100 mM MgCI2, pH 8.5), and 2 J.11 of the
SAP enzyme were brought up to a total volume of 60 1-11 with distilled water and incubated at
37°C for 1 hour.
2.11 KLENOW TREATMENT OF DNA
Klenow (NEB) was used according to the manufacturer's recommendations to fill in 5'
overhangs generated by some restriction enzymes, in order to generate blunt ends. The Klenow
fragment is the large proteolytic product of E. coli. DNA Polymerase I, which retains
polymerization and 3' ~ 5' exonuclease activity but has lost 5'~ 3' exonuclease activity. A
typical reaction mixture contained 0.5 - 1 I-1g of DNA, 4 f..ll of lOX EcoPol buffer (10 mM Tlis-
HCI, 5 mM MgCI2, 7.5 mM DTT, pH 7.5),33 JlM of each dNTP, and one unit of Klenow per J.1g
of DNA in a 40 JlI total reaction volume. The reaction was carried out at room temperature for
15 minutes and then phenol extracted to remove the Klenow and unreacted dNTPs.
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2.12 ENZYME REMOVAL AND EXTRACTION
2.12.1 Phenol Extraction
Prior to ligation or any additional steps involving enzymes, the enzymes used in the
digestion or dephosphorylation had to be removed. One method used for this was phenol
extraction (Sambrook et al., 1989). The volume of the digestion mixture was first brought up to
100 1-11 by adding distilled water. Next, 200 f.11 of cold phenol:chloroform:isoamyl alcohol
(25:24:1) (redistilled phenol, chloroform, isoamyl alcohol, 0.1 % 8-hydroxyquinoline (w/v),
saturated in TE buffer (pH 8) and stored at 4°C) was added to the mixture. The suspension was
mixed gently by inversion for 2-3 minutes and then centlifuged for 5 minutes at 1200 rpm in a
Sorvall MC 12V benchtop centrifuge to separate the phases. The top aqueous layer was
transferred to a new Eppendorf tube, being careful not to include any of the organic layer. Ten
f.ll of 3.5 M sodium acetate (pH 7.5) was then added, followed by 220 f.11 of cold 95% ethanol
and an additional 5 minutes of centrifugation in order to precipitate the DNA. The supelnatant
was then decanted, and the DNA was washed in 200 JlI of cold 70% ethanol. The tube was
vortexed to ensure that the entire pellet was washed, and was then centrifuged again for 5
minutes. The recovered pellet was air dried at room temperature and then resuspended in 20-100
JlI of distilled water or TE buffer (100mM Tlis, 1 mM EDTA; pH 7.8).
2.12.2 Gene Clean From Agarose Gel
Individual bands of DNA can be excised and purified directly from the agarose gel using
the Bio 101 GeneClean® kit. The GeneClean® kit removes salts, RNA, proteins, EtBr and
enzymes from the DNA (Bio 101). In order to excise bands directly from the gel, thicker 0.90/0
agarose gels were made to separate the fragments. A sharp, clean razor blade was used to cut the
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appropriate band from the gel under low UV light, and the band was placed into a previously
weighed Eppendorf tube. The agarose was weighed, and 3 volumes of 6 M NaI stock solution
was added to the Eppendorf tube. The tube was then incubated at 45-55°C for 5 minutes,
mixing occasionally until the gel slice was completely dissolved. Five III of Glassmilk® (a
suspension of silica matrix in water) was then added to the DNA, and the tube was placed on ice
and the contents mixed every 1 to 2 minutes for a total of 5 minutes. The suspension was then
centrifuged for 5 seconds and the supelnatant removed. The pellet was then resuspended in 10 to
50 volumes (usually 300 J..lI) of ice cold NEWTM Wash, using the pipette tip to manually disrupt
the pellet. The DNA was again centrifuged and the supernatant removed, and the wash was
repeated two more times. After the last wash the pellet was completely dried, resuspended in 30
III of TE buffer or distilled water and incubated at 45-55°C for 2 or 3 minutes to elute the DNA.
Lastly, the suspension was centrifuged for 30 seconds to make a pellet, and 20111 of the
supernatant containing the DNA was carefully collected.
2.12.3 Gene Clean From Solution
The Geneclean® kit (Bio 101) can also be used to pUlify DNA that is in solution, in order
to remove restriction and modifying enzymes, and to clean up a reaction mixture. The protocol
is exactly the same as above, however no initial incubation at 45-55°C is required because there
is no agarose to dissolve.
2.12.4 QuickSi Iver™
DNA could also be purified both from agarose gels and in solution using the
QuickSilver™ kit (Norgen Biotek Corp.). The procedure for pUlifying DNA using the
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QuickSilver™ kit is virtually the same as the Geneclean® kit, except that Norgen Binding
Resin is used instead of Glassmilk®. Generally, 10J.ll of resin was used to pUlify DNA, and the
final elution step was canied out at 37°C instead of 45-55°C.
2.12.5 Heat Inactivation
Some enzymes used could be inactivated simply by heating at 65°C for 20 minutes. In
order to determine if an enzyme could be heat inactivated, the suppliers catalogue (NEB) was
consulted. For heat resistant enzymes, one of the previously described methods was used.
2.13 LIGATIONS
DNA ligations were carried out USing T4 DNA ligase (MBI), which catalyzed the
formation of a phosphodiester bond between adjacent nucleotides with a 5' phosphate group and
a 3' hydroxyl group. Ligations were usually left ovelnight at 16°C, or for 1-3 hours at room
temperature. Occasionally, ligations were left overnight at room temperature. Ligation mixtures
usually consisted of 1-2 J.lg of vector DNA, and suitable amounts of insert DNA to give 1:1,1:2
or 1:3 ratios of vector DNA: insert DNA. Also, 1- 10 units of T4 DNA ligase were used, and a
volume of lOX ligase buffer (400 mM Tris-HCl, 100 rnM MgCI2, 100 mM DTT, 5 mM ATP, pH
7.8) that was equal to 100/0 of the total volume. For blunt end ligations, 50/0 PEG 4000 (50%
w/v) was also added. The final volume was obtained by adding distilled water.
2.14 PREPARATION AND LIGATION OF LINKERS
The linkers used for cloning and modification of restliction sites were made from
oligonucleotides (Norgen Biotek Corp.) such that they are dissolved at a final concentration of 1
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pmole/~l. The appropriate amounts of each oligonucleotide required to form a DNA duplex
were mixed in distilled water in an Eppendorf tube, and then heated at 90°C for 5 minutes. The
linkers were then cooled to room temperature in order for annealing to occur, before being used
in subsequent ligations. The ligations were then set up such that 3.5 pmoles of double-stranded
linker were ligated to 0.5 ~g of linearized DNA in a total volume of 20 JlI (D. Bautista, Ph.D.
thesis, McMaster University, Hamilton, Ontaio, Canada, 1984).
2.15 MOLECULAR MODIFICATION OF RESTRICTION ENZYME SITES
Occasionally, it was necessary to eliminate a restliction enzyme site that was present in a
plasmid. Usually this involved a plasmid containing two recognition sites for a particular
restriction enzyme, and one site would be destroyed such that the other site then became a unique
site. The first step involved partially digesting the plasmid with the restriction enzyme, and was
based on the methods of Parker et al. (1977). In a typical reaction, 20 Jlg of DNA, 10 JlI of
appropriate lOX restliction enzyme buffer, 1 unit of restriction enzyme and 2.6 Jlg/ml of
ethidium bromide were added together and brought up to a final volume of 100 J.ll. The
incubation time that resulted in the largest amount of plasmid DNA being cut at only one of the
restriction enzyme sites was determined empilically. For example, 10 JlI aliquots were removed
from the reaction every 5 minutes and the enzymatic reaction was stopped by adding 5 JlI of 6X
loading buffer. The samples were then run on an agarose gel to determine the incubation time
that resulted in the greatest amount of linear DNA.
Once the most desirable incubation time was determined, the reaction was run again and
stopped at this time by the addition of 6X loading buffer. The digest was then run in a thick well
on an agarose gel, and the band excised and pUlified using the Geneclean® kit (Bio 101). The
pUlified, linear DNA would then be treated with Klenow and subsequently ligated together,
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resulting in the destruction of the restriction enzyme site. The plasmids then needed to be
screened to determine which of the two restriction sites had been destroyed.
2.16 AGAROSE GEL ELECTROPHORESIS
After digestion of the DNA, the fragments could be separated and visualized using
agarose gel electrophoresis. Agarose gels were made by dissolving 0.9% w/v agarose in TAE
buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA, pH 8.0), allowing the gel to solidify in a
tray with an appropriately sized comb, and then storing the gel in TAE buffer with 0.15 J.!g/ml
ethidium bromide (EtBr). Generally, 5 f.1l of loading buffer (0.05% bromophenol blue, 20%
glycerol, 2%SDS) was added to the DNA samples, and about 20 ~l of this was loaded into a
well. Nl DNA Ruler (Norgen Biotek Corp.) or PCR-Sizer (Norgen Biotek Corp.) molecular
weight markers were also loaded on to the gel to help in the estimation of fragment sizes. DNA
fragments were separated at 1-10 V/Cffi, and then the gel was viewed under UV light using the
Bio-Rad Gel Doc 1000 system, and photographed using the Multi-Analyst Version 1.1 software
(Bio-Rad).
2.17 POLYMERASE CHAIN REACTION (PCR)
2.17.1 Primers and Reaction Conditions for peR
Primers used in PCR experiments were designed using VECTOR NTI 4.0 software
(InforMax) and synthesized by Norgen Biotek Corp. (St. Catharines, ON). The primers were
typically designed to be 20 to 26 nucleotides in length, possess a GC content of more than 500/0,
and have similar melting temperatures for primer pairs in the range of 56-65°C.
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A typical PCR reaction was car11ed out in 50 ~l volume and contained template DNA,
1-2 units of Taq polymerase (MBl Fermentas), 5 JlI of lOX buffer (100rnM Tris-HCI (pH8.8),
500 mM KCI, 0.8% Nonidet® P40), 0.2 mM of dNTP mix (MBI Fermentas, equal amounts of
dATP, dTTP, dGTP, dCTP), 0.5 uM of forward and reverse primer, and 0.5-2.5 rnM of MgCI2.
The PCR reactions were run in a SingleBlock™ System (Easycycler™ Series, ERICOMP INC.),
with mineral oil being placed over the samples in order to prevent evaporation. Samples were
initially denatured for 3 to 5 minutes at 94°C. Occasionally hot-stali PCR was performed, and
the Taq polymerase and buffer would be added at this point, following the initial denaturation
but prior to the beginning of the cycling. The template DNA was typically amplified in 35 PCR
cycles consisting of a 1 minute denaturation at 94° C, annealing for 1 millute at 52-60°C
(depending on the plimer pair), and extension for 1-2 minutes at 72°C. Following the
completion of the 35 PCR cycles, a final extension was carlied out for 15 minutes at 72°C. For
specific PCR primers and reaction conditions, please see the results section.
2.17.2 Expand™ High Fidelity peR System
For PCR reactions that required a high degree of fidelity, the Expand™ High Fidelity
PCR System was used (Boeluinger Mannheim). The system is composed of a unique enzyme
mix containing thermostable Taq DNA and Pwo DNA polymerases, and is designed to give peR
products with high yield, high fidelity, and high specificity. The PCR reaction volume was again
50 ~l, and contained template DNA, 2.6 units of enzyme mix, 5 ~l of lOX buffer (20 rnM Tris-
HCI, pH 7.5, 100 mM KCI, 1 mM dithiothreitol, 0.1 mM EDTA, 0.50/0 Tween® 20, 0.5%
Nonidet® P40, 50% glycerol) supplemented with 15mM MgC12, 0.2 rnM dNTP mix, and 0.5 uM
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of each primer. The reactions were run in the same machine and using the same programs as
described above.
2.18 MAMMALIAN CELL LINES
The 293 cell line is a human embryonic kidney cell line that was derived by transforming
human cells with mechanically sheared human adenovirus type 5 DNA (Graham et al., 1977).
The cells contain and express the El region of Ad5, and thus are used as a packaging cell line for
El defective adenovirus vectors.
Cells were grown in Minimum Essential Medium (MEM) supplemented with 2 mM
GlutaMAX-1 (Gibco BRL), 0.225% w/v sodium bicarbonate, 10% fetal bovine or horse serum,
and 1% antibiotic/antimycotic [10,000 units/ml penicillin, 10,000 Jlg/ml streptomycin sulfate and
25 Ilg/ml amphotelicin B (Gibco BRL)].
Cells were typically passaged twice a week, when 80-90% confluency was reached. The
medium was removed by aspiration and the cells were washed with 5 ml of IX saline citrate
(134 mM KCI, 15mM Na3C6Hs07.2H20). Subsequently, 3 ml of IX saline citrate was added to
the 150 mm dish and incubated at 37°C until the cells in culture partially detached from the
bottom of the dish. After tapping the side of the dish to assist in complete detachment, the cells
were resuspended in fresh media and split between new dishes in a 1:2 or 1:3 ratio, noting the
passage number on the dish. The cells were maintained in a humid C02 incubator (Fisher
Scientific IsoTemp® incubator; Model 546), which was kept at 37°C and at a 50/0 CO2 level.
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2.19 CELL FREEZING AND THAWING
Cell freezing was calned out as outlined by Freshney (2000). Cells were grown to late
log phase, lifted off the plate using saline citrate, and then centlifuged at 600 rpm for 3 minutes
at room temperature (lEC Centra-8R Centrifuge). The media was aspirated and the cells then
resuspended in 4 ml of fetal bovine serum containing 100/0 dimethyl sulfoxide (DMSO). The
cells were then dispensed into pre-labeled 2m! cryogenic vials (Nalgene). In order to freeze the
cells slowly, the vials were placed on cotton wool in a foam box and placed at -80°C overnight,
after which they were transferred to liquid nitrogen for long term storage.
To recover frozen cell stocks, cells in cryogenic vials were thawed by heating quickly in
a 37°C water bath. Once thawed, the cells were poured into a 150 mm culture plate containing
media supplemented with 10% serum, and swirled well to mix. As soon as the cells attached to
the plate, the media was changed in order to remove the toxic DMSO.
2.20 CALCIUM PHOSPHATE TRANSFECTION
The calcium phosphate procedure used to transfect the 293 cells in this study was based
on the method developed by Graham and van der Eb (1973). The day prior to transfection, cells
were subcultured and plated at a density of 3 x 105 or 5 x 105 cells per 35mm plate. Three hours
before transfection, the media on the cells was changed to media supplemented with 10% fetal
bovine serum. All buffers and solutions were warmed to room temperature prior to transfection.
For each 35 mm plate, either 2 Jlg or 5Jlg of DNA was mixed in TE buffer (pH 8.0) to a final
volume of 90 JlI, to which 10 JlI of 2.5M CaCl2 (filter sterilized) was added. The DNA- CaCl2
mixture was slowly added to 100 JlI of 2X HEPES (280 mM NaCI, 10 mM KCI, 1.5 mM
Na2HP04.2H20, 12 mM dextrose, 50 mM HEPES, pH 7.05, filter sterilized) with constant
mixing. Once combined, the mixture was incubated at room temperature for 1 minute to allow
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for the formation of calcium phosphate - DNA complexes. After the incubation period, the
solution was briefly vortexed and then added dropwise to the cells with constant swirling. The
cells were then incubated at 37°C, and the media changed after 4 hours. Cells were then allowed
to grow for 48 hours, after which time selection began.
2.21 SELECTION WITH GENETICIN
Cultured cells differ widely in their sensitivity to Geneticin (0418; Gibco BRL). The
appropriate concentration to use for selecting stably transfected cells had to be determined
expelirnentally. Non-transfected 293 cells were subjected to varying levels of G418 dUling a 2-
week period to determine the lowest level that would bling about total cell death in that period.
From this it was determined that 150 - 200Jlg/ml of G418 would be the ideal concentration to
use to select stably transfected 293 cells. Thus, 48 hours following transfection, new media
containing 0418 was added to the cells to select for those expressing the neomycin resistance
gene. Fresh growth media containing G418 was added every 4 days, and selection was
maintained for 2 weeks or until all the control cells were killed.
2.22 SELECTION WITH GANCYCLOVIR
Once stably transfected cells had been selected for their resistance to 0418, cells which
had presumably undergone homologous recombination were selected for using Gancyclovir
(GANC, Sigma). GANC is a pro-drug nucleoside analog that, upon expression of a viral gene
encoding thymidine kinase, is converted to its phosphorylated active analog which is
incorporated into the DNA of replicating eukaryotic cells, resulting in cell death. The level of
GANC used for selection (2 x 10-6 M) was based on literature values (Mansour et al., 1988). To
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ensure that 293 cells were not sensitive to GANC, cells were grown for 2 weeks in media
supplemented with 2 x 10-6 M GANC, and no cell death occun4ed.
Selection with GANC began after the 2 week selection in G418. Cells were fed with
media that contained 150 Jlg/ml G418 and 2 x 10-6 M GANC, and again fresh growth media
containing the selective agents was added to the plates every 3 to 4 days. Selection was
maintained for 12 days, after which time G418 f and GANCf colonies could be picked and
expanded.
2.23 ISOLATION OF G41Sr AND GANCr CELLS
2.23.1 Isolation of G41Sr and GANCr Pools
Following the selection in G418 and GANC, several foci were observed to be continually
growing. In order to isolate these foci of interest, pools of cells were selected from the 35mm
dishes through the use of stelile aluminum cloning rings, as described by Freshney (2000). The
foci to be picked were marked on the underside of the dish using a marker. The media was then
removed from the dish, and the cells washed with 1 ml of PBS (140 mM NaCI, 2.6 mM KCl, 4
mM Na2HP04, 1.5 mM KH2P04; pH 7.4). Sterile forceps were then used to dip a cloning ring
in silicone grease (DOW Coming), and then the ling was placed around the desired colonies.
This was repeated for each desired pool in the dish. Following the placement of the lings, each
ring was filled with a few drops of saline citrate, which was then aspirated in order to wash the
cells. The ling was again filled with saline citrate, and the plate was then placed into the 37°C
incubator for 3-5 minutes or until the cells were detached. Once the cells had lifted off the plate,
media was added to each of the lings and the cells were then transfen"ed to a 20mm plate for
expansion.
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2.23.2 Isolation of Single G41Sr and GANCr Foci
Once a promising pool had been identified, single homogeneous foci had to be isolated
from the pools. Media was first aspirated from the well that contained the promising pool, and
the cells were washed twice with 1 ml of PBS. Following washing, the cells were detached from
the plate using a few drops of saline citrate and incubated at 37°C for 10 minutes to ensure that
tlle cells were singly suspended. Two ml of media was then added to the cells, and the cells were
counted using a hemocytometer. Media was then added such that the final concentration of cells
was 2 cells/ml of media. Then, 25 ml of media was transfelTed to a 150mm plate, and the plates
returned to the incubator for growth. Media was changed after 1 week, and after 2 weeks single,
isolated foci could be found. Vacious foci of different size and morphology were then picked
and transferred to 20mm plates using the cloning ling procedure described above.
2.24 HISTOCHEMICAL ASSAY FOR lacZ ACTIVITY
Cells previously transfected with a plasmid carrying the lacZ reporter gene were stained
for lacZ activity. The media was first aspirated from the cells, and then the cells were washed
with 1 ml of PBS. The cells were then overlaid with 1 ml of 4% paraformaldehyde (pH 7.2) and
incubated at 37°C for 2 minutes. The paraformaldehyde was then aspirated and the cells were
washed 2 times with 1 ml of PBS. The cells were then overlaid with 2 ml X-gal stain (35 ruM
K3Fe(CN)6, 35 mM ~Fe(CN)6, 1 mM MgC12, in PBS; pH 7.4, supplemented with 1 mg/mlof
X-gal) and incubated at 37°C overnight. The following day, the number of yellow and blue
cells could be counted and transfection efficiency determined.
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2.25 GENOMIC DNA ISOLATION
Genomic DNA was isolated from cells in the 20mm plates in order to screen for
homologous recombination (Sambrook et al., 1989). Media was first aspirated from the plates,
and the cells were then washed with 500 III of PBS (140 mM NaCI, 2.6 mM KCl, 4 mM
Na2HP04, and 1.5 mM KH2P04, pH 7.4). Five hundred 1-11 of Pronase-SDS lysis buffer (O.OIM
Tris-CI, O.OIM EDTA, 0.5% SDS, 1 mg/ml Pronase; pH7.8) was then added to the cells and
swirled to mix, and the plate was incubated at 37°C for 2 hours. The cell lysate was then
collected into Eppendorf tubes, and 500 1-11 of cold phenol:chloroform:isoamyl alcohol (25:24:1)
(redistilled phenol, chloroform, isoamyl alcohol 0.1 % 8-hydroxyquinoline (w/v), saturated in IE
buffer (pH 8) and stored at 4°C) was added and the contents inverted gently for 10 minutes.
Following mixing, the suspe11sion was centrifuged for 5 minutes at 1200 rpm in a Sorvall Me
12V benchtop centrifuge. The top aqueous layer was then removed and transferred to a new
Eppendorf tube, and an equal volume of water-saturated chlorofom was added. The tubes were
then invelied gently for 10 minutes to remove any traces of phenol. Again the suspension was
centrifuged for 5 minutes, and the upper aqueous layer transfen"ed to a new Eppendorf tube. Ten
percent 3.5 M sodium acetate (pH 7.5) was then added, followed by the addition of 2 volumes of
ice cold 95% ethanol with mixing by inversion until high molecular weight DNA appeared. The
tube was then centrifuged for an additional 3 minutes, the ethanol decanted and the DNA pellet
washed in 200 III of ice cold 70% ethanol. Finally, the tube was again centrifuged for 3
minutes, the supernatant decanted and the DNA pellet resuspended in 100 ~l of MilliQ water and
the concentration determined.
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3. RESULTS
The objective of this project is to modify the 293 packaging cell line (Graham et aI.,
1977) such that replication competent adenovilus formation can be eliminated during
recombinant adenovilus propogation. Currently, 293 cells are used as a packaging cell line for
E1-deficient Ad vectors, because the cells are able to provide the E1 gene products in trans due
to constitutive expression of the Ad5 E1 region. The 293 cells contain the Ad5 genome from
nucleotide 1 to nucleotide 4344 (Louis et al., 1997), and typical E1 replacement vectors contain
homologous sequences on both the left-hand side and right-hand side of the transgene. The
result of this homology is that replication competent adenoviruses can be generated through
homologous recombination between the vector and the packaging cell line, with crossover events
occurling on both sides of the transgene (Figure 5). In this project, the goal is to circumvent the
problem of wild-type reversion by modifying the 293 cells in such a way that the regions of
homology on the left-hand side of the transgene are removed from the cells, and thus a double
crossover event is prevented from OCCUlTing (Figure 5).
In order to modify the 293 cells, a strategy involving homologous recombination was
investigated. A targeting cassette was designed and constlucted, which upon integration into the
293 genome via homologous recombination would result in the removal of the first 380 bp of the
adenoviral genome. Consideling that non-homologous recombination is 1000 times more likely
to occur than homologous recombination (Capecchi, 1990), a number of key features were
incorporated into the constructed cassette so that the chances of generating homologous
recombinants would increase. First, the left cellular-viral junction of 293 cells had to be
included in the cassette to serve as the left-end region of homology. Secondly, a dominant
selectable marker needed to be present in order to select for the cells that had taken up the
A 293 Cells
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Figure 5. The interactions of packaging cell lines and recombinant ~El vectors. Panel A shows
the homologous recombination between 293 cells and adenoviral vectors to generate RCA.
Panel B shows that the new packaging cells cannot generate a double crossover and RCA.
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Figure 6. General outline for the design of the cassette that will be used to modify the 293 cell
line (see text for details).
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3.1 IDENTIFICATION AND CLONING OF THE LEFT CELLULAR-VIRAL
JUNCTION IN 293 CELLS
In order to construct the cassette that will be used to modify 293 cells, it was necessary to
obtain an appropliate region of homology, such as the left cellular-viral junction in the 293 cells.
It has been previously established that the Ad5 sequences in 293 cells extend from nucleotides 1
to 4344 and are located in the pregnancy-specific f3-1-glycoprotein 4 (PSG4) gene (Louis et al.,
1997). This would map the insertion of Ad5 DNA to human chromosome 19 (19q13.2). On the
basis of this information primers were generated so that the appropriate region can be cloned
subsequent to PCR amplification.
The first primer (PSG4-1) was designed to anneal from nt 1 to nt 20 of the PSG4 gene
sequence of Zimmerman et al. (1989). This sequence can be found on Genbank (Accession #
M33665) and is the sequence that Louis et al. (1997) used to establish that the Ad5 sequence is
integrated into the PSG4 gene. The primer was designed to anneal to the extreme end of the
PSG4 gene, such that the largest PCR product possible would be generated, and therefore, the
largest region of homology obtained to construct the cassette. The second primer (FG293) was
designed to anneal from nt 94 to nt 123 of the integrated Ad5 genome (Figure 7). The primer
was generated to anneal to the adenoviral sequences in order to minimize the probability that the
plimer would bind randomly across the human genome. The primers were designed such that a
985 bp product would be generated.
Numerous PCRs were performed using this plimer pair and genomic DNA from 293 cells
as the template. In each case, the results of the PCR were similar. While the expected product
was 985 bp in size, each time the PCR was performed, the product contained numerous bands
resulting in a smearing pattern (Figure 8). Attempts to alter the PCR conditions to improve the
results, such as lengths and temperatures of the annealing and melting steps, did not change the
outcome appreciably. In response to this problem, 2 new primers were generated to attempt a
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nested PCR. The third plimer (PSG4Xma) was designed to anneal from nt 31 to nt 55 of the
PSG4 gene sequence (Accession #M33665), and contained an Xn1aI site on the end to allow for
cloning of the PCR product. This primer was designed so that it annealed at a position
downstream from PSG4-1, yet still allowed for a large region of homology to be obtained in
order to construct the cassette. The fourth primer (293Xba) was constructed to anneal from nt
17 to nt 40 of the AdS genome and contained an XbaI site on the end for cloning of the PCR
product. In this case, the primer was designed such that it was located upstream from the primer
293FG, but again was located close enough to obtain a large amount of the cellular-viral junction
for design of the cassette. The expected PCR product using the new primers was 872 bps (Figure
7).
Nested PCR was then performed using the new primer pair. First, the original PCR was
performed using PSG4-1 and FG293. The resulting PCR product, which contained the numerous
fragments, was then used as the template in the l1ext PCR reaction, and the plimers PSG4Xma
and 293Xba were used (Figure 8). This strategy resulted in the generation of a single PCR
product, which was slightly larger than the expected size of 872 bp (Figure 9). The PCR product
was then digested with XbaI and Xn1aI for cloning into the multiple cloning site of pUC19
(Figure 10). Clones were screened with EcoRI and one paliicular clone, named p293LJ (Figure
11), was selected for further analysis by sequencing.
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A Chromosome 19 (19qI3.2)
Pl~
P3~
B
PSG4
bp 1
~P4
~P2
bp 4344
I Primer I Sequence of Primer (5' to 3') I Location of Primer* [
P1: PSG4-1 GCGGGGTATATTGCAGGACC nt 1 of PSG4
P2: FG293 ATCACACTTCCGCCACACTACTACGTCACC nt 123 of AdS
P3: PSG4Xma TCCCCCCGGGGAAATACGGAACCCAGTGAGTGCCA nt 31 of PSG4
P4:293Xba GCTCTAGATATTGGCTTCAATCCAAAATATGG nt 40 of Ad5
Figure 7. Sequence and location of peR primers used to clone the cellular-viral junction. Panel
A shows the location of the Ad5 sequences in the human genome, as well as the location of
primers 1 - 4. Panel B shows the sequences of primers 1 - 4 as well as their exact location in
terms of the 293 genome (* position of the 5' nucleotide).
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1911 bp
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Figure 8. PCR amplification of the left cellular-viral junction in 293 cells. For this PCR the
plimers PSG4-1 and 293FG were used. Valious PCR conditions were tested as follows: 0.3 J1,g
of genomic DNA template (lanes 1-5); 0.4 J1,g of genomic DNA template (lanes 6-10); 0.5 J1,g of
genomic DNA template (lanes 11-15); 1.0 mM MgCl2 (lanes 1,6,11); 1.5 mM MgCl2 (lanes 2,
7, 12); 2.0 mM MgCl2 (lanes 3, 8, 13); 2.5 mM MgCl2 (lanes 4, 9, 14); and 4.0 mM MgCl2
(lanes 5, 10, 15). M denotes the Norgen Nl molecular weight marker.
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1438 bp
920 bp
Figure 9. Nested PCR amplification of the left cellular-viral juction in 293 cells. The primers
PSG4Xma and 293 Xba were used, and DNA from lane 9 in Figure 8 was used as the template.
Various PCR conditions were tested as follows: 1.0 mM MgCl2 (lane 1); 1.5 mM MgCl2 (lane 2);
2.0 mM MgCl2 (lane 3); 2.5 mM MgCl2 (lane 4). M denotes the Norgen N1 molecular weight
marker.
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Figure 10. Diagram of the strategy to clone p293LJ (see text for details).
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B
c
ORI
Restriction Enzylne Xma I + Xba I AvrIl Hind III
Fraglnent Size (bp) 2675 3683 3683
1008
M abc
9,344 bp _......,,;,::..;;;:.
7,514 bp - ......!W'
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1,438 bp
920 bp
668 bp
Figure 11. Confirmation of p293LJ. Panel A is a restriction map of p293LJ showing the
relevant sites of Xn~aI, XbaI, AvrIl, and HindIII. Panel B is a table showing the expected
fragment sizes when the plasmid is digested with the specified enzymes. Panel C is a picture of
the restriction fragments of p293LJ. The M denotes the Norgen Nl marker, lane a is the Xn~aI
and XbaI digest, lane b is the AvrIl digest and lane c is the HindIII digest.
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3.1.1 SEQUENCE ANALYSIS OF THE LEFT CELLULAR-VIRAL JUNCTION
To precisely analyze the cloned PSG4 fragment, sequencing was carried out at Norgen
Biotek Corp. (St. Cathalines, ON). Alignment of sequencing results was performed using the
web-based BLAST program (Altshul et aZ., 1997) (National Center for Biotechnology
Information, NCBI). As previously stated, the design of the primers to clone the junction was
based on the work by Louis et al. (1997). Unfortunately, the sequencing results of these
researchers were not published, and thus the sequence obtained in this work could not be directly
compared to their sequence. However, Louis and his colleagues determined that the Ad
sequences were integrated into chromosome 19q13.2, and thus, the sequence from p293LJ could
be aligned with chromosome 19 (Accession # AC005392). Furthermore, a group of researchers
from the University of British Columbia (UBC) (Hayashi et LZZ., 2000) have also cloned and
sequenced the cellular-viral junction from 293 cells, and their results are available from the
GenBank database (Accession # AF288220). Thus an alignment was performed between the
three sequences; (1) chromosome 19, (2) the PSG4-Ad5 junction from UBC, and (3) the
sequence obtained from p293LJ.
From the alignments, it was determined that the UBC PSG4 AdS sequence (AF288220)
aligned with chromosome 19 for 850 base pairs to the left of the site of integration of the
adenoviral sequences (Figure 12). Upon alignment of p293LJ, it was found to align with PSG4
AdS for 31 bp of the integrated AdS sequence, and then for 176 bps to the left of the site of
integration (Figure 12). Furthermore, p293LJ was found to align with chromosome 19 for a
stretch of 176 bps left from the site of integration, and then there was a 3928 bp gap, and the
sequence then aligns with chromosome 19 for an additional 767 bps (Figure 12). If the site of
integration of the adenoviral sequences is termed position 1, then this second region of alignment
corresponds to chromosome 19 at positions -4103 to --4870 (Figure 12). Thus, p293LJ appears
to have a deletion from position -175 to --4103, for a total of a 3928 bp deletion. The
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consequences of such a deletion being present in the cell line, as well as the effect of this
deletion on the strategy to generate the targeting cassette are examined in the Discussion section.
A ACOOS392
(chr 19)
C PAM293LJ
D PAM 293LJ
B AF288220(PSG4 AdS)
tI-
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Figure 12. Diagram of the alignment of p293LJ. Panel A corresponds to chromosome 19
(AC005392), with the site of Ad5 integration as position +1. Panel B is the PSG4 Ad5 sequence
(AF288220) generated by the researchers at UBC (see text). Panel C shows the alignment of
p293LJ with both chromosome 19 and PSG4 Ad5, while panel D shows how p293LJ looks
without alignment to the other sequences.
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3.2 CONSTRUCTION OF THE CASSETTE FOR MODIFICATION OF THE 293
CELL LINE
As previously stated, a number of distinct features had to be included in the cassette and
had to be taken into consideration when designing the cloning strategy for the cassette based on
the double selection method of Mansour et al. (1988). The cassette needed to contain; (1) the
cellular-viral junction as the left-end region of homology, (2) the neo gene to use for positive
selection upon transfection into 293 cells, (3) the adenoviral genome from bp 380 to a point
before bp 4344 as the light-end region of homology, and (4) the HSV-tk gene to use for negative
selection. Due to the fact that illegitimate or non-homologous recombination is 1000X more
likely to occur than homologous recombination in eukaryotic cells, the cassette was constlucted
in such a way as to enlich for the probability of generating homologous recombinants (Mansour
et al., 1988).
The overall strategy for construction of the cassette is shown in Figure 13. The details of
each cloning step and the methods used to verify the intermediate plasmids are described in the
following sections. Briefly, the first cloning step involved pXC38, a plasmid which contains the
E1A, E1B and part of the E2 region of the AdS genome (Bautista et al., 1991). This plasmid was
modified through PCR such that the first 380 bps of the adenoviral genome were removed. Next,
a linker was placed into the plasmid, and the AdS sequences from bp 380 to bp 4249 were
subcloned into pUC19. Subsequently, the neo gene from pSV2neo (SouthelTI and Berg, 1982)
was cloned into the plasmid p293LJ, and the neo gene and the cellular sequences were cloned
together as a unit into the pUC-based plasmid containing the adenovirus sequences. Lastly, the
HSV-tk gene from pTK173 was subcloned into pUC19, and finally, the tk gene was cloned from
this plasmid into the adenovirus containing plasmid to generate the modifying cassette PAM2.
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PCR frOln 380bp - 1396 bp
Digest PCR and pXC38 with
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Figure 13. Overall strategy for the constluction of the modification cassette PAM2 (see
subsequent sections for clarification of each step).
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3.2.1 CONSTRUCTION OF pXCdl380
The first step in the constluction of the cassette involved generating the specific 380-bp
deletion. There were a number of reasons for excluding the first 380 bps of the adenovirus
genome. As previously stated, it has been determined that replication competent adenoviruses
(RCA) are generated through recombination between E1 replacement vectors and homologous
sequences in the 293 cell line (Hehir et al., 1996). The mechanism for generating replication
competent revertants in which E1 is reconstituted requires a minimum of two crossovers, one
occurring on either side of the deleted E1. Thus, by removing the adenovirus sequences in the
cell line that are homologous to the adenovirus sequences located on the left-hand side of the
transgene, a double crossing-over event may be prevented from occurring. Elimination of one
crossover (in this case, on the left side of E1) essentially prevents recovery of revertants as
predicted by recombination models (Hehir et al., 1996).
Second, the adenovilus genome is well characterized in this region of interest (Figure
14). It is known that an inverted terminal repeat (ITR) region is located in the first 100 base
pairs of the genome (reviewed in Horitz, 1990). This 380 bp region also contains elements
involved in Ad5 E1A transcriptional control, including enhancer elements (Hearing and Shenk,
1983) and cis-acting packaging elements (Hearing et al., 1987), both located between bp 194 and
358. The core elements of the promoter, the CAAT box and the TATA box are located outside
of this region, with the TATA beginning at bp 469 (Osboulne et al., 1982; Hearing and Shenk,
1983). The E1A cap site is determined by the TATA box and is located at position 499 of the
Ad5 genome. Deletion of the first 380 base pairs of Ad5 would result in the removal of the ITR
along with the enhancer and packaging sequences, without removing the promoter elements
themselves. Thus it was not necessary to replace the E1 promoter with a different promoter,
which would have resulted in the introduction of additional sequences. These additional
sequences might then serve as potential sites for homologous recombination between adenoviral
84
vectors and the cell line, and thus may have been additional locations of recombination
between the cell line and the vectors.
Terminal
Repeat
Enhancer / ~~
Packaging ~~rl) CAAT TATA
Sequences
I
EIA
Coding
Region
Figure 14: Diagram of the 5' region of the Ad5 genome.
In order to generate the 380 bp deletion, PCR was performed on the plasmid pXC38.
This plasmid is 9553 bp in size and contains the adenovirus genome from nucleotide 1 to 5866.
The first PCR primer generated was Ad5 381 Eco, and this primer annealed from nt 437 to 454
of pXC38, or nt 381 to 398 of the Ad5 genome. The primer was generated such that it had an
EcoRI site tagged to the end, which could be used to clone the PCR product. The second PCR
primer generated was Ad5 1346, which annealed from bp 1378 to 1402 of the plasmid pXC38, or
nt 1322 to 1346 of the Ad genome. This primer was generated to contain an XbaI site on the
end, again to be used in cloning the PCR product (Figure 15).
PCR was performed using the Expand™ High Fidelity PCR System (Boehringer
Mannheim), with pXC38 as the template and the plimers Ad5 381 Eco and Ad5 1346. The
Expand™ High Fidelity PCR System was used because it has 3'-5' proofreading activity,
resulting in a 3-fold increased fidelity of DNA synthesis when compared to that of Tag DNA
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polymerase, as claimed by the manufacturer. Therefore, the introduction of errors that ITlay
interfere with the expression of the El region in the cell line would be reduced. The resulting
PCR product was 965 bp in size (Figure 15). The PCR product was digested with EcoRI and
XbaI and was cloned back into pXC38, which was also digested with the same restriction
enzymes. This cloning step resulted in the generation of the plasmid pXCd1380, which contained
the Ad5 genome from base pair 380 to base pair 5866 (Figure 16). The restriction enzyme
confirmation of the plasmid is shown in Figure 17.
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Ad 5 end (5844)
PI
nt 381
EcoRI(l)
Ad5 start nt22
, P2
Xba I (1396) nt 1396
AdS Xhol-C
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Primer I Sequence of Primer (5' to 3')
Pi: Ad5 381 Eco CCGGAATTCAGACTCGCCCAGGTGTTT
P2: Ad5 1346 TCTCTAGACACAGGTGATGTCGGGC
II Location of Primer* I
lint 437 of pXC38 I
lint 1402 of pXC38
c
1911 bp
1438 bp
920 bp
M abc d
Figure 15. Amplification of the Ad5 genome from nt 381 - nt 1396. Panel A shows the
approximate location of the primers on the plasmid pXC38. Panel B shows the sequence of the
primers, and their exact locations on pXC38 (* position of the 5' nucleotide). Panel C shows the
agarose gel of the PCR products. Various PCR conditions were tested as follows: 0.1 J.lg of
pXC38 (lane a); 0.3J.lg of pXC38 (lane b); 0.5 J.lg of pXC38 (lane c). Lane d is a negative control
using pUCI9, and M denotes the Nl Norgen molecular weight marker
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Ad5 start nt22
Xba 1(1396)
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Figure 16. Diagram of the strategy to clone pXCdl380 and pXCAsc (see text for details).
AB
Pst I (8375)
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Bsr G1 (1875)
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Hind III (2430)
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Restriction Enzyme Bsr G 1 Pst I Hind III
Fragment Size (bp) 9122 3771 9122
2210
1282
733
669
430
27
C M ba c
9,344 bp
7,514 bp
5,087 bp
4,539 bp
3,453 bp
1,911 bp
1,438 bp
920bp
668bp
Figure 17. Confirmation of pXCd1380. Panel A is a restriction map of pXCd1380 showing the
relevant sites of BsrGI, PstI, and HindIII. Panel B is a table showing the expected fragment sizes
when the plasmid is digested with the specified enzymes. Panel C is a picture of the restriction
fragments of pXCd1380. The M denotes the Norgen Nl marker, lane a is the BrsGI digest, lane
b is the PstI digest and lane c is the HindIII digest.
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3.2.2 CONSTRUCTION OF pXCAsc
The second step in the construction of the cassette PAM2 involved cloning a linker
containing unique sites into the plasmid pXCd1380, directly in front of the adenoviral sequences.
The linker was designed such that it had an EcoRI tail on one end and an AatII tail on the other
end, with internal NdeI and AscI sites (Figure 16). The strategy to clone the linker involved
digesting pXCdl380 with EcoRI and AatII, inactivating the enzymes with heat, and then ligating
the digested plamid to the prepared linker (Figure 16). This procedure resulted in the generation
of the plasmid pXCAsc, which contained the unique NdeI and AscI sites that could then be used
for cloning additional fragments required in the cassette. The confirmation of the plasmid's
structure is shown in Figure 18.
AAd5 end (5844)
Asc [(9065)
Hind III (2430)
90
B
c
Restriction EnzyIne Asc I Asc 1+ Bgl II Asc I + Hind III
Fraglnent Size (bp) 9071 6111 6635
2960 2436
M abc
9,344 bp
7,514 bp
5,087 bp
4,539 bp
3,453 bp
1,911 bp
1,438 bp
920bp
668 bp
Figure 18. Confirmation of pXCAsc. Panel A is a restriction map of pXCAsc showing the
relevant sites of AscI, BgIII, and HindIII. Panel B is a table showing the expected fragment sizes
when the plasmid is digested with the specified enzymes. Panel C is a picture of the restriction
fragments of pXCAsc. The M denotes the Norgen Nl marker, lane a is the AscI digest, lane b is
the AscI and BglII digest and lane c is the AscI and HindIII digest.
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3.2.3 CONSTRUCTION OF pUCAsc
The next step in the construction of the cassette involved cloning the pXCAsc fragment
containing the AdS genome with the desired deletion into pUC19. The reasons for this step were
two-fold. First of all, by cloning pXCAsc into pUC19, the copy number would be increased, and
therefore it would be easier to obtain larger amounts of the final construct in order to perform the
transfections. Secondly, the linker was designed such that it contained unique restriction enzyme
sites which would then be convenient for cloning additional pieces of the cassette. However, it
was determined after cloning in the linker that an NdeI site was actually present in the backbone
of the plasmid, and thus the site that was contained within the linker was not unique. Therefore
by performing the subcloning step, the NdeI site in the linker would become unique.
The strategy for the cloning of pUCAsc is shown in Figure 19. The subcloning was
accomplished by first digesting pXCAsc with the restliction enzyme ApaI, and then heat
inactivating the enzyme. The ends were then filled in with Klenow polymerase, such that blunt
ends were generated. The linearized plasmid was then digested with ACItII, and again the enzyme
was heat inactivated. Simultaneously, the plasmid pUC19 was double digested with AatII and
PvuII. The resulting fragments were run on an agarose gel, and the 1,991 bp pUC19 sub-
fragment was purified from the gel. The pUC19 fragment was then ligated to the pXCAsc
fragments, and the resulting plasmids were screened. Restriction enzyme analysis verified that
the plasmid pUCAsc was generated (Figure 20). This plasmid could then be used in subsequent
cloning steps in order to generate the final constluct for modification of the 293 cells.
Aar II (9052)
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Ad5 end (5844)
Apa 1(4555)
Ad5 dl380
Ad5 end (4249)
Digest with ApaI,
Klenow,
Digest with AatII
Ligate and Transform
Aal II (6261)
Ad5dl380
Digest with PvuII and
AatII
Figure 19. Diagram of the strategy to clone pUCAsc (see text for details).
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AdS end (4249)
NdeI(6)
AdS dl380
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c
Restriction Enzyme NdeI Asc I Asc I + Hind III
Fraglnent Size (bp) 6261 6261 3825
2436
Ma b c
9,344 bp
7,514 bp
5,087 bp
4,539 bp
3,453 bp
1,911 bp
1,438 bp
920 bp
Figure 20. Confirmation of pUCAsc. Panel A is a restriction map of pUCAsc showing the
relevant sites of NdeI, AscI, and HindIII. Panel B is a table showing the expected fragment sizes
when the plasmid is digested with the specified enzymes. Panel C is a picture of the restriction
fragments of pUCAsc. The M denotes the Norgen Nl marker, lane a is the NdeI digest, lane b is
the AscI digest and lane c is the AscI and HindIII digest.
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3.2.4 CONSTRUCTION OF pSV2-neo-Asc and pSV2-neo-Asc2
The next cloning steps involved the plasmid pSV2neo, which contains the neo gene from
Tn5 under control of the SV40 early promoter, as well as a polyadenylation signal for expression
in mammalian cells (SouthelTI and Berg, 1982). The neo gene confers resistance to the antibiotic
kanamycin in bacteria, and to the amino-glycoside antibiotic 0418 in mammalian cells. For ease
of cloning, AscI linkers were inserted on either side of the neo gene and its accompanying
regulatory and expression sequences.
In order to construct pSV2-neo-Asc, a linker with Ban1HI sites on both ends and an
internal AscI site was designed and synthesized. Subsequently, pSV2-neo was digested with
Ban1HI, the enzyme was removed, and the linker was ligated to the linearized plasmid (Figure
21). This effectively resulted in converting the Ban1HI site to an AscI site. The structure of the
desired plasmid is verified in Figure 22.
The construction of pSV2-neo-Asc2 involved similar steps. However in this case, the
AscI linker was designed with NdeI sites on both ends. The plasmid pSV2-neo-Asc was then
digested with NdeI, and the AscI linker was ligated to the digested plasmid (Figure 21). The
plasmid pSV2-neo-Asc2 was verified through restriction enzyme analysis (Figure 23). The
resulting plasmid was similar to pSV2-neo, with the exception that the neo gene was now
flanked by AscI sites. Thus, it was a simple one-step procedure to clone out the neo gene, by
digesting pSV2-neo-Asc2 with AscI.
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SV400RI
BalllH I (752)
E POLY A
E POLY A
L POLY A
NEO(R)
AscI
GATCC GGCGCGCC
CCGCGCGG CCTAG
Digest with BalnHI
Ligate and Transform
NEO(R)
Nde I (3677)
SV400RI
pSV2-neo-Asc
5739 bp
E POLY A AscI
TA GGCGCGCC
CCGCGCGG AT
Digest with NdeI
Ligate and Transform
Asc 1(3682)
pSV2-neo-Asc2
5750 bp
Asc I (759)
E POLY A
E POLY A
L POLY A
SV400RI
Figure 21. Diagram of the strategy to construct pSV2-neo-Asc and pSV2-neo-Asc2 (see text for
details).
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NEO(R)
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Restriction Asc I + Hind III Asc I + Eco RI AscI+BgIII
EnzyIne
Fraglnent Size 3395 4981 3715
(bp) 2344 758 2024
C M ba c
9,344 bp
7,514 bp
5,087 bp
4,539 bp
3,453 bp
1,911 bp
1,438 bp
920 bp
Figure 22. Confirmation of pSV2-neo-Asc. Panel A is a restriction map of pSV2-neo-Asc
showing the relevant sites of AscI, HindIII, EcoRI and BglII. Panel B is a table showing the
expected fragment sizes when the plasmid is digested with the specified enzymes. Panel C is a
picture of the restriction fragments of pSV2-neo-Asc. The M denotes the Norgen Nl marker,
lane a is the AscI and HindIII digest, lane b is the AscI and EcoRI digest and lane c is the AscI
and BglII digest.
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Restrictio11 Asc I Asc I + Eca RI Asc I + BgI II
Enzylue
Fragluent Size 2923 2923 2827
(bp) 2827 2069 2024
758 899
M abc
9,344 bp
7,514 bp
5,087 bp
4,539 bp
3,453 bp
920bp
668 bp
Figure 23. Confirmation of pSV2-neo-Asc2. Panel A is a restriction map of pSV2-neo-Asc2
showing the relevant sites of AscI, EcoRI and BglII. Panel B is a table showing the expected
fragment sizes when the plasmid is digested with the specified enzymes. Panel C is a picture of
the restriction fragments of pSV2-neo-Asc2. The M denotes the Norgen Nl marker, lane a is the
AscI digest, lane b is the AscI and EcoRI digest and lane c is the AscI and BglII digest.
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3.2.5 CONSTRUCTION OF p293LJ-neo
The next cloning step in the construction of the gene targeting cassette involved the
plasmid pSV2-neo-Asc2, as well as the plasmid p293LJ. As stated previously, p293LJ contains
the cellular-viral sequences from the 293 cells cloned into pUC19. This cloning step involved
removing the neo gene from pSV2-neo-Asc2 and inserting it next to the cellular sequences
(Figure 24). In order to accomplish this, p293LJ was digested with XbaI and then treated with
Klenow polymerase in order to generate blunt ends. Next, the plasmid pSV2-neo-Asc2 was
digested with AscI, followed by treatment with Klenow polymerase, again generating blunt ends.
The fragment containing the neo gene was then blunt-end cloned into the plasmid p293LJ. In
order to facilitate selection, the transformed bacteria containing the plasmids for screening were
plated on agar plates containing both ampicillan and kanamycin. The resulting plasmid, p293LJ-
neo, contained the cellular-viral junction sequences followed by the neo gene, complete with all
regulatory sequences necessary for expression in mammalian cells. This plasmid was confirmed
by digestion with several indicative restliction enzymes, which not only confirmed the integrity
of the plasmid but also allowed for the determination of the orientation of the neo gene (Figure
25).
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Figure 24. Diagram of the strategy to clone p293LJ-neo and p293LJ-neo-Ad5 (see text for
details).
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Restriction Enzyme Hind III
Fragment Size (bp) 5995
603
Pvu II
2364
2100
762
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360
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3434
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c M abc
9,344 bp
7,514 bp
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Figure 25. Confirmation of p293LJ-neo. Panel A is a restriction map of p293LJ-neo showing
the relevant sites of HindIII, PvuII and AvrIl. Panel B is a table showing the expected fragment
sizes when the plasmid is digested with the specified enzymes. Panel C is a picture of the
restriction fragments of p293LJ-neo. The M denotes the Norgen Nl marker, lane a is the HindIII
digest, lane b is the PvuII digest, and lane c is the AvrIl digest.
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3.2.6 CONSTRUCTION OF p293LJ-neo-Ad5
The previously constructed plasmid pUCAsc was then used along with the plasmid
p293LJ-neo to generate the next intermediate clone. This step involved taking the cellular-viral
sequences together with the neo gene, and cloning these elements into pUCAsc directly before
the adenoviral sequences (Figure 24). This strategy was accomplished by first digesting pUCAsc
with EcoRI, and then treating the linealized plasmid with Klenow polymerase. Next, the
plasmid p293LJ-neo was digested with Acc651 and Sail and was then also treated with Klenow
to generate blunt ends. The resultant two fragments were then run on an agarose gel, and the
larger fragment containing the cellular sequences and the neo gene was pUlified from the gel.
This blunt-end fragment was then ligated into the blunt-end plasmid pUCAsc, resulting in the
generation of p293LJ-neo-Ad5. The plasmid was verified through restriction enzyme analysis
(Figure 26). The resulting plasmid contained the cellular-viral junction, the neo gene, and the
adenoviral sequences from bp 380 to bp 4249.
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Restriction Enzyme Hind III
Fragment Size (bp) 7181
3014
XmaI
2933
2538
2521
2023
180
Pvu II
4669
1861
1482
762
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360
320
171
C M ba c
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7,514 bp
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3,453 bp
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Figure 26. Confirmation of p293LJ-neo-Ad5. Panel A is a restriction map of p293LJ-neo-Ad5
showing the relevant sites of HindIII, Xn'laI and PvuII. Panel B is a table showing the expected
fragment sizes when the plasmid is digested with the specified enzymes. Panel C is a picture of
the restriction fragments of p293LJ-neo-Ad5. The M denotes the Norgen Nl marker, lane a is
the HindIII digest, lane b is the XmaI digest, and lane c is the PvuII digest.
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3.2.7 CONSTRCUTION OF pUC-TK
The next piece of the cassette that needed to be cloned was the tk gene, which was to be
used for negative selection. The source of the gene was the plasmid pTK173, which contains the
entire HSV-tk gene (PvuII) fragment cloned into pBR322 at the PvuII site (reviewed in Haj-
Ahmad and Graham, 1986). This PvuII fragment of the HSV-tk gene contains all the promoter
and enhancer elements necessary for tk gene expression in mammalian cells (Smiley, 1985;
Jones et al., 1985). To facilitate the cloning of the tk gene into the plasmid p293LJ-neo-Ad5, the
gene was first sub-cloned into pUC19 (Figure 27). First the plasmid pTK173 was digested with
PvuII, and then treated with shlimp alkaline phosphatase. Next, pUC19 was digested with
HincII, and then the PvuII fragment from pTK173 was cloned into the plasmid. Screening for
the desired plasmid was facilitated by the use of X-gal containing plates and the process of u-
complementation. The resulting plasmid, pUC-TK, contained the tk gene within the HincII site
of pUC19. This plasmid was velified through digestion with a number of indicative restrcition
enzymes, which not only confirmed the structure of the plasmid but also the orientation of the tk
gene within. the plasmid (Figure 28).
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Figure 27. Diagram of the strategy to clone pUC-TK and PAM2 (see text for details).
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Figure 28. Confirmation of pUC-TK. Panel A is a restriction map of pUC-TK showing the
relevant sites of EcoRI, PstI, Ban'lHI and BglII. Panel B is a table showing the expected
fragment sizes when the plasmid is digested with the specified enzymes. Panel C is a picture of
the restriction fragments of pUC-TK. The M denotes the Norgen Nl marker, lane a is the EcoRI
digest, lane b is the PstI digest, and lane c is the Ban'lHI and BglII digest.
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3.2.8 CONSTRUCTION OF PAM2
In order to construct the final cassette PAM2, the tk gene from pUC-TK needed to be
cloned into the plasmid p293LJ-neo-Ad5. This was a relatively straight forward procedure,
considering that both of these plasmids are pUC-based (Figure 27). First, p293LJ-neo-Ad5 was
digested with ScaI and SCIclI, and the resulting two fragments were run on a gel. The larger
fragment, containing the cellular sequences, the neo gene and the adenovirus sequences, was
then purified from the gel. Next, pUC-TK was also digested with Scal and Sacll and the
fragments were run on a gel. The larger fragment, containing the tk gene was also purified from
the gel. The two isolated bands were then ligated together, and resulted in the plasmid PAM2.
The plasmid was verified through restriction enzyme analysis (Figure 29).
This final constluct now contains: (1) 1001 bps of the cellular-viral junction from 293
cells, (2) the neo gene under contol of the SV40 promoter, with an SV40 polyadenlyation signal,
(3) the adenoviral sequences from bp 381 to bp 3834, (4) and the tk gene under control of its own
promoter and polyadenlyation sequence. This cassette can now be used to modify 293 cells
through the process of homologous recombination, in order to generate the new cell line of
interest (Figure 30). This new cell line will be identical to current 293 cells, except that the first
380 bp of the adenoviral genome will be removed and will be replaced with the neo gene. This
380 bp deletion will eliminate the sequences in the cell line homologous to the left-hand side of
the transgene in E1-deleted adenoviral vectors, and will thus eliminate the possibility for double
crossovers and the generation of RCA.
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Figure 29. Confirmation of PAM2. Panel A is a restliction map of PAM2 showing the relevant
sites of HindIII, PvuII, and XmaI. Panel B is a table showing the expected fragment sizes when
the plasmid is digested with the specified enzymes. Panel C is a picture of the restriction
fragments of PAM2. The M denotes the Norgen Nl marker, lane a is the HindIII digest, lane b is
the PvuII digest, and lane c is the Xn1aI digest.
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Figure 30. Generation of the modified 293 cell line through homologous recombination
between the engineered cassette and the 293 cell line.
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3.3 ESTABLISHMENT OF THE MODIFIED 293 CELL LINE
Once the cassette had been engineered, the next step was to transfect the 293 cells with
the casette in order to generate the new cell line. When DNA is introduced into mammalian
cells, it integrates randomly over the genome by 2-5 orders of magnitude more frequently than
homologous recombination occurs (Vega, 1991). Thus, the cassette was designed such that
positive/negative selection could be used. Th~s procedure can be used to enrich by 2000-fold for
those cells that have taken up the construct through homologous recombination (Mansour et ai.,
1988).
The cassette contained a neo gene for positive selection, such that all cells that have taken
up the construct through either homologous or nonhomologous recombination will be resistant to
the drug 0418. The cassette also contained the HSV-tk gene adjacent to one of the regions of
homology. In this case, homologous recombination will result in the HSV-tk gene not being
transferred into the 293 cells. The HSV-tk gene is lost during the process of homologous
recombination because it is located distal to the region of homology between the vector and the
target in the cells. Only cells in which random integration of the targeting vector occurred will
be able to retain the HSV-tk. Therefore, by using 0418 to select for cells that contain a
functional neo gene and by using gancyclovir to select against cells that have a functional HSV-
tk gene, one can enrich for cells that have undergone the expected double crossover.
3.3.1 DETERMINATION OF THE LEVEL OF G418 TO BE USED FOR SELECTION
Cell lines differ widely in their sensitivity to 0418, and thus, the concentration to be used
for selecting stably transfected cells had to be determined experimentally. As described in
Materials and Methods, non-transfected cells were subjected to varying levels of 0418 during a
two-week period to determine the lowest level that would bring about total cell death in that
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period. The results of two trials are summarized in Tables 3 and 4. From the results, it was
determined that 150-200 f.1g/ml of G418 would be the ideal concentration to use to select stably
transfected 293 cells.
Table 3. Results of varying concentration of G418 on Plate 1 of 293 cells over a two-
week period (percentages are estimates of the number of surviving cells, where 100% is a fully
confluent plate).
G418 Concentration Plate 1 Plate 1 Plate 1 Plate 1
t= 0 weeks t = 1 week t= 1.5 weeks t = 2 weeks
50 ug/ml 100% 100% 75% 800/<
100 ugml 100% 90% 35% 200/<
150 ug/ml 100% 55% 5% 5%
200 ug/ml 100% 20% 0% 0%
250 ug/ml 100% 5% 0% 0%
control 100% 0% 0% 0%
Table 4. Results of varying concentration of G418 on Plate 2 of 293 cells over a two-week
period (percentages are estimates of the number of surviving cells, where 100% is a fully
confluent plate).
G418 Concentration Plate 2 Plate 2 Plate 2 Plate 2
t = 0 weeks ~= 1 week ~ = 1.5 weeks t = 2 weeks
150 ug/ml II 100o/~1 100o/~1 70o/~1 50%1
100 ugml 100<X 90% 40<X 10%
150 ug/ml 100<X 60% 5<x 0%
200 uglml 100<X 20% O<X 0%
250 uglml 100<X 5% O<X 0%
control 100<X 0% O<X 0%
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3.3.2 DETERMINATION OF THE LEVEL OF GANCYCLOVIR TO BE USED FOR
SELECTION
The HSV-tk gene causes susceptibility to the non-toxic pro-drugs gancyclovir and
acyclovir. However, it has been previously determined that gancyclovir is a better choice to use
for selection in targeting experiments (Mansour et al., 1988). The level of GANC to be used in
these transfections was based on literature values and was 2 x 10-6 M (Mansour et al., 1988).
Although it has been previously shown that neither the morphology or viability of 293 cells is
affected by GANCup to concentrations of 80 J.1M (Imler et al., 1995), the experimental level of
GANC needed to be tested on the 293 cells to be used for transfection. Thus, as described in the
Materials and Methods, 293 cells were grown for two weeks in media supplemented with 2 x
10-6 M GANC and were compared to 293 cells that were grown in regular media. After the two
week period, the cells grown in GANC were morphologically identical to the control cells, and
no cell death had occurred (Figure 31). Thus, this was an acceptable level of GANC to use for
selection of transformants.
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Figure 31. Effect of GANC on 293 cells. Panels A and C show 293 cells that have been
exposed to 2 x 10-6 M GANC for 1 week and 2 weeks respectively, and panels Band Dare
control 293 cells after 1 and 2 weeks respectively. Magnification is 100X.
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3.3.3 CALCIUM PHOSPHATE TRANSFECTION OF 293 CELLS
In order to establish the modified 293 cell line, the PAM2 construct was transfected into
293 cells. The calcium phosphate technique (Graham et al., 1973) was employed, as desclibed
in Materials and Methods, and a total of 17 tranfections were performed. Typically, either 2 Jlg
or 5Jlg of NdeI linearized vector was used and 5 x 106 cells were transfected. Linearization of
the vector outside of the region of homology has been shown to increase the frequency of
homologous recombination (Smithies et al., 1985; Hasty et al., 1991; Yanez and Porter, 1998).
Selection for cells that had integrated the constluct either randomly or through homologous
recombination began 2 days after transfection and involved the use of 150-200 Jlg/ml of G418.
Selection proceeded for approximately 2 weeks, or until all the control cells for a given
experiment had been killed (Figure 32). Next, selection began on the G418 f pools in order to
eliminate the cells that had undergone nonhomologous recombination. Selection with GANC
proceeded for approximately 1Y2-2 weeks, until all the GANC sensitive colonies had been
destroyed, resulting in a number of G418 f + GANCf colonies that could be picked and expanded
for screening (Figure 33).
The promising foci were picked using cloning lings and were transferred to 24-well
plates. The cells were expanded and then split, with one plate being maintained in the incubator
while genomic DNA was extracted from the other plate. A total of 100 pools of Q418 f + GANC f
foci were picked for screening.
Ac
B
D
114
Figure 32. Transfection and selection of 293 cells. Panel A shows 293 cells prior to
transfection, and panel B shows 293 cells after 8 days of selection in 200 J.lg/ml 0418, with some
cell death beginning. Panel C shows total cell death in control 293 cells after 16 days selection
in 200 IJ,g/ml 0418, and panel D shows some 0418 f transfected cells after 16 days selection in
200 J.lg/ml 0418. Magnification is 100X.
115
A
B
Figure 33. Examples of G41S f and GANef foci. Panels A and B depict foci that were present
after 16 days selection in 200 J.!g/ml G418 and 8 days selection in G418 + 2 x 10-6 M GANC.
Magnification is 100X.
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3.3.4 SCREENING OF G41Sr + GANCr POOLS
PCR was used in order to screen the cell lines, to determine if the construct had been
integrated into the 293 genome via homologous or non-homologous recombination. One set of
plimers was generated to screen specifically for the desired 380-bp deletion. Primer 1 was
designed to anneal from nt 112 to nt 136 of the adenoviral genome, while plimer 2 annealed
from nt 496 to nt 520. If the constluct had integrated through non-homologous recombination,
then a 408 bp product would be generated. However, if the cell line had undergone homologous
recombination with the vector, the first 380 bp of the adenoviral genome would be deleted, and
thus, there would be no PCR product generated (Figure 34).
The absence of a PCR product is not a definitive test, as the PCR may fail for numerous
reasons. Therefore, a second set of plimers was generated to be used as positive control. Primer
3 annealed from nt 1021 to nt 1045 of the adenoviral genome, and primer 4 annealed from nt
1511 to nt 1535. Since this region is located outside of the 380 bps that were to be deleted, then
this primer pair should generate a 514 bp product regardless of whether the cells have undergone
homologous or non-homologous recombination (Figure 35).
The 100 isolated pools of G418 f + GANC f cells were then screened using the first primer
paIr. The absence of a product was promising for the 380 bp deletion, and the PCR would be
repeated in these cases (Figures 36 and 37). If there was still no formation of a PCR product,
then more genomic DNA would be isolated from these cells and the PCR would be performed
again using both the test primers and the control plimers. In many cases, cells which had
initially been giving a negative signal for the 380 bp region were now showing amplification
products using the first plimer pair (Figure 38). Possible reasons for this are explored in the
Discussion section. However, ten pools of G418 f + GANCf cells were deemed to be promising
and, therefore, needed to be subcloned in order to isolate homogenous cell lines. This was done
through single-cell cloning by the end-point dilution technique, as described In the
Materials and Methods.
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A 293 Cells
B New Cell Line
PI (nt 112) P2 (nt 520)
~~t---
Product: 408 bp
118
nt 381 nt 4344
C
No Product
I Primer I Sequence of Primer (5' to 3') I Location of Primer*1
P1: Ad5 - For ~GGAA9TGTGATGTTGCAAGTGTGG nt 112 of Ad5 J- ~ -- - -P2: Ad5 - Rev CTACTCGCTGGCACTCAAGAGTGG nt 520 of Ad5
Figure 34. Strategy for the screening of homologous recombinants by peR amplification. Panel
A shows that a 408 bp product will be generated if the cell line has undergone non-homologous
recombination, and panel B shows that no product will be formed if the cells have undergone
homologous recombination with the constlUCt. Panel C shows the sequence of the primers as
well as their exact location in terms of the 293 genome (* position of the 5' nucleotide).
A 293 Cells
B New Cell Line
C
P3 (nt 1021) P4 (nt 1535)
~.-/
Product: 514 bp
P3 (nt 1021) P4 (nt 1535)
~.-/
Product: 514 bp
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Primer II Sequence of Primer (5' to 3')
P1: Ad5 - ForCon CAGGTCTTGTCATTATCACCGGAGG
P2: Ad5 - RevCon GGCGTTTACAGCTACAGTCCAAAGG
II Location of Primer* I
nt 1021 of Ad5
nt 1535 of Ad5
Figure 35. Diagram of the positive control to be used in the screening process for homologous
recombinants. Panels A and B show that a 514 bp product will be formed if the cells have
undergone homologous recombination or non-homologous recombination with the constlUCt.
Panel C shows the sequence of the primers as well as their exact location in terms of the 293
genome (* position of the 5' nucleotide).
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A
M 1 2 3 4 5 6 7 8 9 10 1112 13 14 15 16 17 +-
500 bp
400bp
B
M 20 2122 23 24252627 28 29 30 3132 33 34353637 38 394041 + -
500bp
400bp
Figure 36. Examples of agarose gel pictures of the first round of PCR screening for homologous
recombinants. M denotes the Norgen PCR-Sizer marker, + is the positive control of 293
genomic DNA, and - is the negative control of no DNA. The numbers indicate different
genomic DNA samples. In panel A, samples 4, 11, 12 and 17 show negative signals, while in
panel B, samples 24, 35, 37, 39 and 41 exhibit negative signals.
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M 50 51 52 53 54 55 56 57 58 +
SOObp
400bp
Figure 37. Example of an agarose gel picture of the first round of PCR screening for
homologous recombinants. M denotes the Norgen PCR-Sizer marker, + is the positive control of
293 genomic DNA, and - is the negative control of no DNA. The numbers indicate different
genomic DNA samples. Samples 54 and 57 show negative signals for the 380 bps.
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M 4 4 1717 2424 3535373739 39414154 54 5757 + + - -
SOObp
400bp
Figure 38. Example of an agarose gel picture of the second round of PCR screening for
homologous recombinants. M denotes the Norgen PCR-Sizer marker, + is the positive control of
293 genomic DNA, and - is the negative control of no DNA. The numbers indicate different
genomic DNA samples. Samples 4, 17, 54 and 57 are now showing positive signals for the 380
bp region, while samples 24, 35, 37, 39 and 41 look promising for the deletion of the 380 bp
region.
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3.3.5 SCREENING OF G41Sr+ GANCr FOCI
As stated, the cells from the ten most promising pools were diluted to single cells, and
plated in large plates at a concentration of 50 cells/plate such that individual, homogeneous foci
could grow. Ten foci from each of these plates were then picked using cloning lings and again
transferred to 24-well plates to allow for expansion. Genomic DNA was isolated from these
cells, and the same process of PCR screening for detection of homologous recombinants was
employed (Figure 39). From the initial screening, eight samples looked promising for the
deletion of the 380 bp and thus homologous recombination. Again, the PCR was repeated and
additional genomic DNA was extracted from the cells. Upon performing the final peR in which
both plimer pairs were used, all the samples showed a positive signal for the 380 bps (Figure 40).
Possible reasons for these results are desclibed in the Discussion section.
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A
M 1 2 3 4 567 8 91011121314151617181920 + -
500bp
400bp
B
M 30 31 32 3334 35 3637 3839 40 414243 44 4546 47 4849 + -
500 bp
400bp
Figure 39. Examples of agarose gel pictures of the first round of PCR screenIng of
homogeneous foci for homologous recombinants. M denotes the Norgen PCR-Sizer marker, + is
the positive control of 293 genomic DNA, and - is the negative control of no DNA. The
numbers indicate different genomic DNA samples. In panel A, samples 8, 11, and 20 show
negative signals, while in panel B, samples 32, 34, 36, 39 and 47 exhibit negative signals.
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M 47 47 8 8 11 11 20 20 39 39 3232 3434 3636 + + -
500 bp
400bp
Figure 40. Example of an agarose gel picture of the second round of PCR screening of
homogeneous foci for homologous recombinants. M denotes the Norgen PCR-Sizer marker, + is
the positive control of 293 genomic DNA, and - is the negative control of no DNA. The
numbers indicate different genomic DNA samples. All samples show a positive signal for the
presence of the 380 bp region.
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4. DISCUSSION
The generation of replication competent adenoviruses (RCA) is a major problem that
faces the use of recombinant adenovirus vectors for gene therapy. The presence of RCA in Ad
vector batches that are to be used clinically is undesirable and constitutes a major safety risk.
The main concern is that replication competent vectors may provide helper functions to the
replication-defective vectors, and may lead to uncontrolled amplification and spread of the
replication-defective vector viruses (Imler et ai., 1995). Furthermore, the RCA may result in
aggravation of the host immune response to give rise to inflammation and tissue damage (Fallaux
et ai., 1998). As a result of these potential problems, regulatory bodies such as the Food and
Drug Administration (FDA) of the United States have taken the position that RCA are
unacceptable in adenoviral vector preparations for clinical use (Fallaux et ai., 1998).
Although the FDA takes this position, strict guidelines have not yet been established as to
the level of RCA that is acceptable in vector preparations, nor is there a standardized test for
RCA. There are inconsistencies in what analytical methods are used to quantitate RCA, and
RCA testing IS not consistent among different manufacturers
(www.fda.gov/cber/minutes/aden020101.htm). Therefore the FDA has taken a conservative
approach and assumed that there is a safety lisk associated with RCA; however, they have not
determined what level is actually safe. Furthermore, the FDA suggests that a cell
culture/cytopathic effect method be used to test for RCA, but they do not indicate input
multiplicity of infection (MOl), what cells to pelform the test on, or what volume of production
lot should be tested (www.fda.gov/cber/somgene.txt). The FDA also suggests that the assay be
quantitative; however, in application the test is usually semi-quantitative and involves a yes or no
answer (www.fda.gov/default.htm). All these factors lead to huge inconsistencies in RCA
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testing, and potential dangers for patients involved in Ad gene therapy trials. The FDA is
currently working on developing an adenoviral standard that would deal with not only the issue
of RCA, but also various other issues facing the use of adenoviral vectors in clinical tlials such
as virus generation and dose levels (www.fda.gov/cber/minutes/aden020101.htm).
Studies have shown conclusively that RCA are generated by homologous recombination
between vectors and 293 cell Ad5 sequences (Hehir et al., 1996; Zhu et al., 1999). It has been
determined that 293 cells contain the Ad5 genome from the terminal left-end to nucleotide
position 4344 (Louis et al., 1997). There are various ways to make E1 deletion vectors;
however, the most common ones result in at least 350-450 nucleotides of homologous sequence
on the left side of the transgene and about 800 bp of homology on the right of the transgene
(Hehir et al., 1996). Analysis of RCA isolates indicates that dual recombination events to the
left and right of the transgene result in the loss of the transgene and acquirement by the vector of
the E1 region (Hehir et al., 1996). One strategy to achieve RCA-free Ad preparations is to
remove the homologous sequences from either side of the transgene in order to eliminate the
possibility of homologous recombination tllrough a double crossover.
Many different groups of researchers have attempted to overcome the problem of RCA
generation in 293 cells. Traditionally, this has involved attempts to establish new packaging cell
lines or to modify the adenoviral vector backbone. Hehir and colleagues found a reduction in the
rate of RCA formation in 293 cells through the deletion or rearrangement of pIX gene sequences
within the adenoviral vectors, but this strategy did not completely eliminate RCA formation
(Hehir et al., 1996). Imler et al. isolated an A549 cell line transfected with a plasmid containing
E1A and E1B open reading frames with the contiguous pIX (bp 505 to 4034), in which E1A is
dliven by a phosphoglycerate kinase (PGK) promoter. This cell line does not generate RCA
from a vector deleted of only E1A and E1B (bp 104 to 3329) (Imler et al., 1996). Another group
has developed a new packaging cell line and matched adenoviral vectors (Fallaux et al., 1998).
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The PER cells produced by Fallaux et ale contain the Ad5 genome from nucleotides 459-
3510 under control of the PGK promoter, and the matched Ad vectors do not have any sequence
overlap. Propagation of the matched Ad vectors in the PER cells does not result in the
generation of RCA. Furthermore, the cell line has no sequence overlap between integrated
adenoviral DNA and vector DNA of commonly used vectors. Schniedner and colleagues (2000)
have established adenovirus packaging cell lines by transfecting primary human amniocytes with
the Ad5 El region. The generation of RCA was excluded in these cell lines by designing the
transforming plasmid to lack the first 505 bp of the adenoviral genome, and thus sequence
overlap with current adenoviral vectors on the left-hand side of the transgene. Gao et ale (2000)
have developed a HeLa-based cell line, GH329, which contains the Ad5 El region from bp 511
to 3924 under control of the PGK promoter. There is no overlap with the 5' region of standard
E1-deleted vectors and reduced overlap at the 3' end. Again, this cell line does not result in the
formation of RCA upon serial passaging of an E1-deleted virus (Gao et al., 2000). Lastly, Kim
et ale (2001) have also developed a HeLa-based packaging cell line, that contains and expresses
the minimal E1 gene. This HeLa-El cell line was shown to produce no RCA during a minimal
number of passages of an E1-deleted vector (Kim et aI., 2001). Thus a number of researchers
have overcome the problem of RCA formation through the generation of new packaging cell
lines.
As mentioned earlier, there is no standardized test for the presence of RCA, and there are
numerous variations in testing. For example, Fallaux et ai. (1998) performed a detailed
cytopathic effect (CPE) assay involving 2 cell lines to test for RCA. The assay involved
infecting HeLa cells with the virus at an MOl of <25, waiting 4 days and then passing a freeze-
thaw lysate of the HeLa cell culture assay on to cultures of A549 cells. The observation of either
individual plaques or widespread CPE was taken as an indication of the presence of RCA in the
initial dose (Fallaux et al., 2001). Gao et ale (2001) also used a CPE assay to test for the
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generation of RCA. However, in their case 1 x 108 PFU of virus was added to A549 cells,
and infected cells fron1 each plate were harvested and lysed 14 days later. The lysate was
applied to A549 cells, and after 7 days the plates were examined for CPE. It is difficult to
directly compare the results from these two groups due to the fact that the initial amount of virus
tested was measured in different ways, and the amount and type of cells being used for the assay
are different. Perhaps RCA may have been detected by one of the groups if they had used the
other testing method. A completely different metl10d used to screen for RCA was PCR (Kim et
ale 2001). The PCR was based on detecting the presence of the E1A gene in the DNA isolated
from virus. This method of RCA detection is very different from the CPE assays used by the
other two groups, and again it is difficult to compare results because of these inconsistencies.
Furthermore, Kim et al (2001) tested for the presence of RCA after only two passages through
the cell line, while Gao et al. (2000) tested for RCA after 20 passages. It is important to keep
these ideas in mind when considering the value of a new packaging cell line in terms of RCA
formation.
In this research, it was decided that instead of following the traditional methods of
generating a new packaging cell line to eliminate the generation of RCA, the 293 cell line itself
would be modified. The first 380 bps of the adenoviral genome would be removed from the
cells, and therefore the regions of homology on the left-hand side of most commonly used E1-
deleted vectors would be removed. Thus, there would be no possibility of a double-crossover
event occun"ing, and the generation of RCA would be eliminated.
The method that was used to modify the 293 cell line was the process of homologous
recombination, or gene targeting. Gene targeting is essentially the homologous recombination of
DNA sequences residing in the chromosome with newly introduced DNA sequences, and it
provides a means for systemically altering the mammalian genome (Jasin et al., 1985; Smithies
et al., 1985; Thomas et al., 1986, Thomas and Capecchi, 1987). The main drawback for gene
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targeting is that it is quite inefficient, and typically the absolute efficiency ranges from 10-5
to 10-7 targeted cells per transfected cell (Yanez and Porter, 1998). Furthermore, when DNA is
introduced into mammalian cells, it integrates randomly over the genome by 2-5 orders of
magnitude more frequently than homologous recombination occurs (Vega, 1991). The ratio of
homologous to non-holl1010gous recombination in mammalian cells is about 1: 1,000 (Capecchi,
1990). Researchers have been very interested in determining ways to increase the frequency of
homologous recombination, as well as developing methods that can help to screen for
homologous recombinants.
Many points were taken into consideration when designing the modification cassette
PAM2. Firstly, it has been determined that one of the key factors in efficient homologous
recombination is the use of isogenic DNA to prepare the vector (Riele et al., 1992). On average,
vectors prepared from isogenic DNA are four to five times more efficient than con4 esponding
vectors prepared from nonisogenic DNA (Deng and Capecchi, 1992). Therefore, in this project
the cellular-viral junction was cloned from genomic DNA that was isolated from the 293 cell line
that would ultimately be used for transfections.
Secondly, the cassette was designed such that the emichment procedure of positive-
negative selection (PNS) could be employed (Mansour et al., 1988; Capecchi, 1989).
Essentially, this procedure uses a positive selection for cells that have incorporated the targeting
construct anywhere in the genome, and a negative selection against cells that have randomly
integrated the vector. The vector is designed to calTY the left-hand region of homology, a neo
gene, the right-hand region of homology, and the HSV-tk gene. This vector was designed such
that hOll1010gous recombination will result in the HSV-tk gene not being transfelTed into the 293
cell line. The HSV-tk gene is lost because it is located distal to the right-hand side region of
homology, and only cells in which random integration of the targeting vector has occurred will
be able to retain the HSV-tk gene. Therefore, by selecting for cells that contain a functional neo
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gene and by using GANC to select against cells that contain a functional HSV-tk gene, one
can enrich for cells in which the targeting event has occurred. This procedure has been found to
enrich 2,000-fold for cells that contain a targeted alteration (Mansour et al., 1988).
Lastly, it was important to construct the cassette such that it had a sufficient amount of
homology to allow for homologous recombination. It is widely accepted that recombination
frequency decreases as the length of homology is reduced (Rubnitz and Subramani, 1984; Hasty
et al., 1991; Deng and Capecchi, 1992). There is some discrepancy regarding the minimum
amount of homology required, and whether it is the total amount of homology present that has
the greatest effect on targeting frequency, or the length of homology on the short arm. Rubnitz
and Subramani (1984) have reported very low recombination frequencies with as little as 14 base
pairs of hOll1010gy (Rubnitz and Subramani, 1984). Hasty et ale (1991) determined that 472 bp
of homology on one arm is used as efficiently as 1.2 kb in the formation and resolution of cross-
over junctions. Furthermore, they determined that the total length of homology has a greater
impact on targeting efficiency than the length of homology on the short arm (Hasty et al., 1991).
Contrary to these findings, Thomas et ale (1992) found that it is a reduction in arm length rather
than a reduction in the total amount of absolute homology that led to inaccurate recombination.
They determined that if one arm of the construct contains less than 1 kb of homologous DNA,
aboltive recombination can occur (Thomas et al., 1992). In the present study, the construct
PAM2 contained 1001 bps of DNA that spans a region that is homologous to the cell line on the
short arm, and 3454 bp of homologous DNA on the long arm. Therefore, the total amount of
homology is 4455 bp, which is deemed sufficient for recombination.
The first task of this project was to clone the cellular-viral junction from 293 cells, which
would serve as one arm of homology in the cassette. PCR amplification was used to clone the
junction, and the design and location of the plimers are described in Section 3.1 of Results. The
primer design was based on the work of Louis et ale (1997), who determined that the AdS
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sequences in 293 cells are integrated into chromosome 19, at the PSG4 gene. The plasmid
p293LJ was constructed and sequenced, and the sequence was analyzed using BLAST (Altschul
et al., 1997). Upon alignment of the p293U sequence and chromosome 19, it was found that the
293 cell line used in this work appears to contain a 3928-bp deletion. The p293LJ sequence
aligns with chromosome 19 from the point of AdS integration back for 176 base pairs, and then
aligns from -4104 to -4871 on chromosome 19, using the site of Ad integration as O. Therefore,
it appears that there is a 3928 bp deletion from -176 to -4104 (Figure 11). It should be noted
that low passage number 293 cells were used for this thesis, and that the cells had just recently
been purchased plioI' to the peR amplification of the cellular-viral junction.
This deletion is not surprising, consideling the fact that this is a laboratory cell line that
l1as been grown and passaged since 1977 (Graham et al., 1977). As in any other cells, processes
such as insertions, deletions, translocations and recombination are OCCUlTing frequently. The
main selective pressure on these human embryonic kidney cells is that the El region of AdS is
being expressed. The only other selective pressure on this cell line would be for growth and
maintenance functions. The PSG4 gene, into which the AdS sequences are integrated, belongs to
the human pregnancy-specific ~l glycoprotein family. These are a group of glycoproteins which
are synthesized in large amounts by placental trophoblasts. During pregnancy, PSG is released
to the maternal circulation and, as pregnancy progresses, an increasing concentration of PSG is
found in matelnal blood (Khan et al., 1992). Although the PSGs were discovered more than 25
years ago, their function is still unknown (Teglund et al., 1994). Therefore, it does not appear
that this PSG4 gene would supply any necessary function for the growth and maintenance of the
293 cells, and that a large deletion in this gene family would not be detrimental to the integrity of
the cell line.
The second objective of this project was to construct the gene targeting cassette PAM2.
The design and components of the cassette have been discussed previously. All plasmid
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intermediates for the construction of the cassette were verified by restriction enzyme
analysis and agarose gel electrophoresis.
The third objective was to transfect 293 cells with the constructed cassette. Numerous
transfection methods are available for use with mammalian cells including the calcium phosphate
technique, electroporation, Lipofectamine, and injection of DNA. In this case, the calcium
phosphate procedure was chosen, due to its attractive features including (a) it is a very efficient
method to use with 293 cells, (b) it is relatively easy to perform and inexpensive, and (c) it was
invented by the same researchers who initially developed the 293 cell line (Graham and van der
Eb, 1973). Calcium phosphate transfections have been previously shown to be successful in a
number of gene targeting experiments (Smith and Berg, 1984; Lin et al., 1985; Jasin et al., 1985;
Jasin and Berg, 1988; Wang et al., 1995; Mathews et al., 1999).
The transfection and selection procedures were performed as desclibed in the Materials
and Methods section. Linearization of the targeting construct has been found to increase the
frequency of homologous recombination (Smithies et al., 1984; Jasin et al., 1985; Thomas et al.,
1986; Yanez and Porter, 1998). Linear DNA molecules appear to be much more recombinogenic
in mammalian cells than their cOITesponding supercoiled molecules (Thomas et al., 1986). It has
been found that the location of the linealization site on either the 5' or 3' region of homology
does not alter the targeting frequency (Hasty et al., 1991). The targeting vector PAM2 was
linearized prior to transfection using NdeI, which cut the cassette outside of the 5' region of
homology.
A total of 17 transfections were performed. Selection would begin with G418 after two
days, and continued for approximately two weeks or until all the control cells were killed for a
given experiment. Typically, from the 500,000 cells that were initially transfected, the number
of G418 f cells would be too many to count. This would correspond to hundreds of G418 f cells,
which is comparable to literature values for other gene targeting experiments (Lin et al., 1985;
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Smith and Berg, 1984; Thomas et al., 1986). These G418 f cells represent any cell that has
integrated the construct, either through random or homologous recombination. Upon selection
with GANC, a large number of the G418 f colonies would be killed, until approximately 3-14
G41S f + GANCf colonies would remain. Ideally, these colonies would represent only the cells
tllat had taken up the construct through homologous recombination. The cells would then be
picked for screening using cloning rings. These cells should be viewed as pools at this point for
two reasons. First, it would be incorrect to assume that these colonies arose from a single cell,
due to the fact that there were 500,000 cells initially present in these 35mm dishes. Second,
when the foci were picked using cloning lings, often more than one focus would be included due
to the large size of the cloning rings. Thus, these should be viewed as pools of G418 f and
GANCf cells.
A number of different methods are available to screen for homologous recombination.
Initially, genomic Southern blots were the screening method of choice and were used almost
exclusively in gene targeting experiments (Thomas and Capecchi, 1986; Hasty et al., 1991; Deng
et al., 1993). However, the popularity of Southern blots has recently been diminished with the
arlival of PCR-based assays (Kim and Smithies, 1988; Wang and Taylor, 1993; Abrahams et al.,
1998). Novel methods for screening have also been developed, including an ELISA-based
method (Williams et al., 1994). Considering that PCR had already been used and termed
efficient in this study, along with the fact that it is quick and requires extremely small amounts of
DNA, PCR was chosen as the screening method for detection of homologous recombinants.
Normally when using PCR to screen for homologous recombinants, the basic strategy is
to select plimers such that amplification can only occur when homologous recombination has
taken place. One primer is chosen from the region unique to the construct and the other primer is
chosen from genomic DNA sequences in the chromosome but outside of the region of interest
(Frohman and Martin, 1990). In this case it was difficult to design the PCR plimers this way,
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due to the fact that the inserted neo gene and regulatory sequences were so large (~3 kb),
and the only difference between the new cell line and the 293 cell line is the presence or absence
of the 380 bp region. Thus the screening strategy outlined in the results section was employed,
in which two pairs of primers were used. The first pair would result in a product only if the 380
bp were present, and therefore homologous recombination had not OCCUlTed (Figure 33). The
second primer pair was designed to amplify in the case of both homologous and non-homologous
recombination, and thus' acted as a positive control (Figure 34).
Genomic DNA was isolated from the G41Sf + GANef colonies, and was initially
screened using the first primer pair. If the result of the PCR was negative, the screen was
repeated to ensure that the PCR did not fail. If the result was still negative, then additional
genomic DNA was extracted from the promising cell lines, and subjected to peR using both the
plimer pairs. Initially, 100 pools of G418f + GANCf colonies were screened. From this, 10 of
the pools looked promising because they gave negative results for the plimer pair that was
detecting the 380 bp region (Figures 35 and 36). However, upon re-isolation of genomic DNA
and PCR with both pairs of primers, a number of samples tilat initially looked promising were
now giving positive signals for the 380 bp region. In Figure 37, samples 4, 17, 54 and 57 now
appear to be positive when they were initially negative. One explanation for this could be the
notion that these are pools of cells. Initially, a pool may have contained a vast majority of the
desired cell line, with only a very small percentage of parental 293 cells. Thus, when genomic
DNA was first isolated and screened, it would appear to be negative for the presence of the 380
bp region. It could be the case, however, that the desired cell line with the 380 bp deletion has a
reduced growth rate as compared to the parental 293 cells, and thus when genomic DNA was
again isolated from the cells at a later date, the pool may have become overgrown by the parental
293 cell line. In this case, when the PCR was again performed, the pool would test positive for
the presence of the 380 bps. There have been examples in literature where recovery of clonal
136
cell lines from complex pools is extremely difficult due to clonal vmiablility in growth rates
(Shichi11 etaZ., 1993; Hanson and Sedivy, 1995).
A number of different explanations exist for why the desired cell line may have a reduced
growth rate as compared to the parental 293 cells. The decision to remove the enhancer region
of the El promoter may play a role in this idea of clonal variability in growth rates. As
previously stated, the enhancer and packaging sequences were removed from the targeting
construct, while only the core elements of the promoter remained. Essentially, by deleting the
first 380 bps from the Ad genome, only the TATA box element of the promoter remained. This
should be sufficient to drive expression of the El region; however, the level of expression will be
greatly reduced. In deletion studies of the El region, it was found that deleting the enhancer
region from bp 194 to bp 358 resulted in mRNA levels that were 0.07 of the wild-type level
(reviewed in Berk, 1986). Thus, the level of EIA expression will be greatly reduced, and this
may lead to altered morphology and growth. characteristics. When El expression was
completely eliminated in 293 cells through the use of antisense EIA, the cells were unable to
survive and underwent senescence (Quinlan, 1993). The expression of the EIA region in 293
cells is clearly required for immortilization, and lowering the level of EIA expression may affect
the growth characteristics of the cells. Therefore, the desired cell line which contained a deletion
of the enhancer region ll1ay have exhibited reduced growth when compared to the pm"ental 293
cell line.
Based on this idea of mixed populations of cells and valiable growth rates, the 10 pools
that initially tested negative for the 380 bps were deemed to be promising pools. In order to
isolate out the cell line of interest, the pools were diluted to single cells and plated in a 150 mm
plate at a density of 50 cells/plate. After two weeks, ten homogeneous foci from each plate were
picked using cloning rings and expanded. Genomic DNA was isolated from the cells and again
screened using the same procedure. From this round of screening, eight of the cell lines looked
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promising due to the lack of a product when amplifying the 380 bp region (Figure 38).
Additional genomic DNA was isolated from tl1ese pools, and screened using both sets of primers.
As can be seen in Figure 39, all the samples which initially appeared promising were now giving
rise to positive signals for the 380 bp region.
A number of explanations exist for why the pools initially appeared promising but then
gave lise to positive signals. First, although the cells were treated with saline citrate to render
them as single cells and thus homogeneous foci, many of the foci may have arose from more
than one cell. It is difficult to separate single cells, and if the cells are under-treated by the
chemical they may produce clumps, while if they are over-treated the viability of the cells will be
reduced (Freshney, 2000). Therefore, although many of the cells appeared as single cells under
the microscope, two or three cells may have been clumped together in some cases. This could
then result in the same phenomena that was previously discussed, in which the desired cell line
has reduced growth rates and the pool becomes overgrown by the parental 293 cells. Second, it
is possible that either the cell lines became contaminated with wild-type 293 cells, or the peR
became contaminated with 293 cell genomic DNA. When performing the peR, genomic 293
DNA was used as the positive control, which constitutes a risk for contamination. Kim et clI.
(1991) ran into this problem of contamination in their laboratory despite the use of a separate
room, together with dedicated micro-pipettes and solutions, laminar flow hoods, gloves, caps and
gowns for the setting up of peR assays.
Due to the initial promising screening results, we feel confident that the cell line with the
desired deletion is present in the pools of cells. Additional cloning and pUlification of the cell
lines must be performed, with the utmost care taken to ensure that contamination does not occur.
Once the cell line is isolated, it must then be characterized in tenns of physiological
characteristics, transformation efficiency, viral growth and stability. Once isolated and
characterized, this cell line will prove invaluable for the growth and packaging of EI-deleted
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vectors. Due to the lack of homology on the left-hand side of the transgene in most
common E1 vectors, the cell line will be unable to undergo a double-crossing over event with the
vector. Therefore, RCA will be prevented from occul1.ing and the cell line can be used
confidently and safely for the production of recombinant adenoviruses to be used in human gene
therapy.
5. SUMMARY
In summary, based on the results obtained in this study, the following conclusions can be stated:
1) The left cellular-viral junction from 293 cells was cloned into the plasmid p293LJ, and the
junction was sequenced.
2) The 293 cell line used in this study appears to contain a 3928 bp deletion in the PSG4 gene
located at the cellular-viral junction.
3) The targeting vector PAM2 was constructed in order to modify the 293 cell line, and
contained the left cellular-viral junction, the neo gene, the AdS genome from bp 381 to bp
3834, and the HSV-tk gene.
4) Preliminary results are promising that the desired cell line with the 380 bp deletion is present
within the isolated cell lines, and further cloning and purification of the cell lnes must be
performed in order to isolate the homogeneous cell line.
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